MeSH term
Frequency | Condition_Probility | Female | 301 | 0.0 |
Humans | 1679 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 9 | 0.0 |
Acute Disease | 13 | 0.0 |
Adult | 292 | 0.0 |
Bone Marrow Transplantation/*statistics & numerical data | 2 | 2.0 |
Comparative Study | 133 | 0.0 |
Cord Blood Stem Cell Transplantation/*statistics & numerical data | 2 | 2.0 |
Fetal Blood/transplantation | 2 | 2.0 |
Leukemia/*therapy | 2 | 1.0 |
Patient Selection | 3 | 1.0 |
Cell Culture Techniques | 16 | 3.0 |
Motor Neurons/*physiology | 2 | 3.0 |
Base Sequence | 126 | 0.0 |
DNA/genetics | 7 | 0.0 |
DNA-Binding Proteins/*metabolism | 11 | 0.0 |
Gene Expression Regulation | 47 | 1.0 |
In Vitro | 108 | 1.0 |
Jurkat Cells | 152 | 11.0 |
Molecular Sequence Data | 198 | 0.0 |
Nuclear Proteins/*metabolism | 4 | 0.0 |
Promoter Regions (Genetics) | 32 | 0.0 |
Receptors, Antigen, T-Cell/*metabolism | 26 | 17.0 |
Research Support, U.S. Gov't, P.H.S. | 496 | 0.0 |
Signal Transduction | 177 | 3.0 |
T-Lymphocytes/immunology/metabolism | 19 | 15.0 |
Transcription Factors/*metabolism | 9 | 0.0 |
Antigens, Surface/genetics/metabolism | 2 | 15.0 |
Research Support, Non-U.S. Gov't | 1141 | 0.0 |
Structure-Activity Relationship | 10 | 0.0 |
Time Factors | 62 | 0.0 |
Animals | 539 | 0.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
DNA-Binding Proteins/metabolism | 19 | 1.0 |
*I-kappa B | 11 | 6.0 |
Immunosuppressive Agents/*pharmacology | 24 | 11.0 |
JNK Mitogen-Activated Protein Kinases | 29 | 5.0 |
Lymphocyte Activation/drug effects | 35 | 6.0 |
Mice | 335 | 1.0 |
Mice, Inbred BALB C | 65 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 14 | 1.0 |
Phosphorylation | 104 | 1.0 |
Protein-Serine-Threonine Kinases/metabolism | 12 | 1.0 |
T-Lymphocytes/drug effects/immunology | 12 | 13.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 16 | 2.0 |
*Adaptor Proteins, Signal Transducing | 21 | 1.0 |
Antigens, CD3/immunology | 86 | 31.0 |
Cell Division/drug effects | 30 | 0.0 |
Cells, Cultured | 305 | 1.0 |
Enzyme Activation | 52 | 1.0 |
Interleukin-2/*biosynthesis/pharmacology | 2 | 10.0 |
MAP Kinase Signaling System | 5 | 1.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 3 | 0.0 |
Mitogen-Activated Protein Kinase 3 | 4 | 0.0 |
T-Lymphocytes/drug effects/*immunology | 17 | 11.0 |
Adolescent | 60 | 0.0 |
Aged | 124 | 0.0 |
Antigens, Differentiation/*genetics | 28 | 20.0 |
Case-Control Studies | 23 | 0.0 |
Genotype | 12 | 0.0 |
*Immunoconjugates | 221 | 63.0 |
Male | 287 | 0.0 |
Middle Aged | 200 | 0.0 |
Polymerase Chain Reaction | 42 | 0.0 |
Polymorphism, Genetic | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Antigens, CD/genetics/physiology | 2 | 12.0 |
Antigens, CD28/genetics/immunology | 2 | 66.0 |
Antigens, CD4/genetics | 2 | 3.0 |
Antigens, Neoplasm/*analysis | 3 | 0.0 |
CD40 Ligand/genetics/immunology | 3 | 100.0 |
*Cancer Vaccines | 6 | 23.0 |
Cytotoxicity, Immunologic | 59 | 6.0 |
Graft Rejection | 5 | 3.0 |
Immune Tolerance | 25 | 8.0 |
Interferon Type II/deficiency/genetics/physiology | 2 | 50.0 |
Mice, Knockout | 33 | 1.0 |
Mice, Transgenic | 30 | 1.0 |
Neoplasm Transplantation | 11 | 0.0 |
Gene Expression | 41 | 0.0 |
Gene Therapy/*methods | 5 | 1.0 |
Genetic Vectors/*administration & dosage/genetics | 2 | 12.0 |
Liver/metabolism | 2 | 0.0 |
Rats | 28 | 0.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 6 | 5.0 |
Antigens, CD/physiology | 24 | 11.0 |
Antigens, CD80/physiology | 19 | 57.0 |
Cytokines/biosynthesis | 57 | 10.0 |
Isoenzymes/metabolism | 7 | 1.0 |
Membrane Glycoproteins/physiology | 12 | 7.0 |
Phospholipase C/metabolism | 9 | 3.0 |
Protein-Tyrosine Kinase/physiology | 5 | 4.0 |
Signal Transduction/immunology | 60 | 18.0 |
Transcription, Genetic/immunology | 14 | 17.0 |
Cell Division | 75 | 1.0 |
Disease Models, Animal | 13 | 0.0 |
*Immunotherapy/methods | 2 | 28.0 |
Lymphocyte Activation | 312 | 9.0 |
Neoplasms/immunology/*therapy | 4 | 7.0 |
T-Lymphocytes/immunology | 73 | 5.0 |
Antigens, CD3/analysis | 11 | 4.0 |
Antigens, CD4/analysis | 13 | 3.0 |
DNA, Viral/analysis | 5 | 1.0 |
Flow Cytometry | 205 | 3.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Receptors, Chemokine/analysis | 3 | 10.0 |
T-Lymphocytes/chemistry/immunology | 2 | 14.0 |
Transduction, Genetic/methods | 2 | 8.0 |
Cell Communication/immunology | 9 | 11.0 |
Cell Line, Transformed | 17 | 1.0 |
Enzyme Activation/immunology | 21 | 16.0 |
Lymphocyte Activation/*immunology | 89 | 20.0 |
Protein Transport/immunology | 2 | 11.0 |
Protein-Tyrosine Kinase/*metabolism | 21 | 2.0 |
Receptors, Antigen, T-Cell/immunology/metabolism/*physiology | 3 | 75.0 |
Receptors, Immunologic/*physiology | 13 | 7.0 |
T-Lymphocytes/*enzymology/*immunology/metabolism | 4 | 80.0 |
Tyrosine/metabolism | 27 | 2.0 |
CHO Cells | 53 | 2.0 |
Cell Line | 148 | 0.0 |
Down-Regulation/genetics/immunology | 4 | 14.0 |
Enzyme Activation/genetics | 3 | 3.0 |
Enzyme Inhibitors/pharmacology | 24 | 0.0 |
HIV-1/*genetics | 6 | 1.0 |
Hamsters | 67 | 1.0 |
Mutagenesis, Site-Directed | 20 | 0.0 |
Signal Transduction/genetics/*immunology | 7 | 8.0 |
Transcription, Genetic/*immunology | 4 | 12.0 |
Up-Regulation/genetics/immunology | 5 | 8.0 |
Tumor Cells, Cultured | 131 | 0.0 |
Antigens, CD28/metabolism | 76 | 80.0 |
Antigens, Differentiation/chemistry | 3 | 60.0 |
Binding Sites | 38 | 0.0 |
Crystallography, X-Ray | 4 | 0.0 |
Dimerization | 7 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 13 | 0.0 |
Glycosylation | 8 | 0.0 |
Protein Binding | 34 | 0.0 |
Protein Folding | 3 | 0.0 |
Protein Isoforms | 3 | 0.0 |
Protein Structure, Tertiary | 17 | 0.0 |
T-Lymphocytes/metabolism | 12 | 4.0 |
Antigens, CD28/immunology/*metabolism | 13 | 92.0 |
Membrane Microdomains/*metabolism | 4 | 8.0 |
Microscopy, Confocal | 6 | 0.0 |
Phosphoproteins/metabolism | 8 | 1.0 |
Receptors, Antigen, T-Cell/immunology/*metabolism | 2 | 20.0 |
Antigens, CD28/*genetics | 21 | 100.0 |
Celiac Disease/*genetics | 4 | 14.0 |
Child | 45 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Genetic Predisposition to Disease | 9 | 0.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*physiology | 8 | 36.0 |
Transfection | 107 | 0.0 |
Antigens, CD28/*metabolism | 97 | 96.0 |
Apoptosis | 30 | 1.0 |
CD8-Positive T-Lymphocytes/*immunology | 45 | 14.0 |
Epstein-Barr Virus Infections/immunology | 2 | 25.0 |
Herpesvirus 4, Human/*immunology | 4 | 5.0 |
Infectious Mononucleosis/*immunology | 2 | 10.0 |
*Lymphocyte Activation | 235 | 17.0 |
*Antigens, CD | 30 | 3.0 |
Antigens, CD28/biosynthesis | 22 | 73.0 |
Antigens, CD3/*metabolism | 12 | 25.0 |
Calcium/metabolism | 35 | 2.0 |
Cell Nucleus/metabolism | 10 | 0.0 |
Dose-Response Relationship, Drug | 22 | 0.0 |
Genetic Vectors | 9 | 0.0 |
HIV-1/*metabolism | 2 | 0.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/metabolism | 5 | 9.0 |
*Nuclear Proteins | 29 | 1.0 |
Transcription Factors/metabolism | 19 | 1.0 |
*Transcription, Genetic | 10 | 0.0 |
Aging/*immunology | 24 | 20.0 |
CD8-Positive T-Lymphocytes/cytology/*immunology | 5 | 18.0 |
Epitopes, T-Lymphocyte/immunology | 8 | 8.0 |
Immunophenotyping | 106 | 3.0 |
Interferon Type II/biosynthesis | 51 | 11.0 |
Mice, Inbred C57BL | 69 | 1.0 |
Nucleoproteins/immunology | 2 | 16.0 |
*RNA-Binding Proteins | 3 | 0.0 |
Viral Core Proteins/immunology | 2 | 8.0 |
Antigens, CD3/metabolism | 32 | 19.0 |
Apoptosis/drug effects | 7 | 1.0 |
Gene Expression Regulation/drug effects | 12 | 1.0 |
Interleukin-2/*pharmacology | 8 | 3.0 |
L-Selectin/metabolism | 2 | 6.0 |
Receptors, Interleukin-2/metabolism | 23 | 12.0 |
Antigens, CD28/*physiology | 87 | 93.0 |
Drug Resistance | 8 | 1.0 |
Interleukin-2/biosynthesis/genetics | 9 | 22.0 |
Signal Transduction/*drug effects | 7 | 1.0 |
T-Lymphocytes/drug effects/metabolism | 3 | 8.0 |
Antigens, CD28/physiology | 63 | 77.0 |
Antigens, Dermatophagoides | 4 | 7.0 |
Chemokines/biosynthesis/genetics | 2 | 11.0 |
Chemotaxis, Leukocyte | 2 | 1.0 |
Glycoproteins/immunology | 4 | 4.0 |
Hypersensitivity/*immunology | 5 | 10.0 |
Macrophages, Alveolar/*physiology | 2 | 13.0 |
RNA, Messenger/analysis | 34 | 1.0 |
Receptors, Chemokine/genetics | 3 | 6.0 |
Th2 Cells/*immunology | 13 | 10.0 |
Cytokines/biosynthesis/genetics | 4 | 6.0 |
Interleukin-2/genetics | 14 | 16.0 |
Lymphocyte Function-Associated Antigen-1/physiology | 4 | 9.0 |
T-Lymphocytes/*immunology | 301 | 13.0 |
Aged, 80 and over | 40 | 0.0 |
*Aging | 4 | 2.0 |
Antigens, CD28/*blood | 10 | 100.0 |
Antigens, CD8/*blood | 2 | 6.0 |
Antigens, Differentiation/*blood | 2 | 11.0 |
Lymphocyte Count | 35 | 5.0 |
T-Lymphocyte Subsets | 10 | 7.0 |
Antibodies, Monoclonal/immunology | 75 | 4.0 |
Isoantigens/immunology | 9 | 10.0 |
Kinetics | 46 | 0.0 |
RNA, Messenger/biosynthesis | 19 | 1.0 |
Trans-Activation (Genetics) | 12 | 0.0 |
Adjuvants, Immunologic/genetics/physiology | 2 | 100.0 |
CD8-Positive T-Lymphocytes/*cytology/*immunology/metabolism | 2 | 66.0 |
Cell Division/immunology | 51 | 17.0 |
Cytokines/*biosynthesis | 24 | 6.0 |
Interleukin-2/biosynthesis | 85 | 19.0 |
Ligands | 88 | 3.0 |
*Lymphocyte Activation/genetics | 3 | 11.0 |
Receptors, Tumor Necrosis Factor/biosynthesis | 2 | 11.0 |
T-Lymphocyte Subsets/cytology/immunology/metabolism | 3 | 25.0 |
T-Lymphocytes, Cytotoxic/immunology | 25 | 6.0 |
Tumor Necrosis Factor-alpha/genetics/*physiology | 2 | 8.0 |
*Immunologic Memory | 19 | 13.0 |
Interferon Type II/*biosynthesis | 13 | 8.0 |
Acquired Immunodeficiency Syndrome/*immunology | 3 | 1.0 |
Antigens, CD/analysis | 36 | 2.0 |
Antigens, CD40/physiology | 7 | 24.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 6 | 3.0 |
Cell Adhesion Molecules/physiology | 7 | 7.0 |
Cell Communication | 14 | 4.0 |
Cell Differentiation | 32 | 1.0 |
HIV-1/*immunology | 24 | 4.0 |
Immunoglobulins/*biosynthesis | 2 | 4.0 |
Interleukin-6/pharmacology | 5 | 1.0 |
Monocytes/*physiology | 3 | 1.0 |
*Apoptosis | 18 | 1.0 |
Intestinal Mucosa/*immunology | 3 | 3.0 |
T-Lymphocytes/*immunology/physiology | 9 | 24.0 |
Antibodies, Monoclonal/metabolism | 11 | 3.0 |
Genes, MHC Class I | 2 | 1.0 |
Membrane Proteins/*physiology | 3 | 2.0 |
T-Lymphocyte Subsets/classification/*immunology | 3 | 33.0 |
T-Lymphocytes, Cytotoxic/classification/*immunology | 2 | 13.0 |
Antigen Presentation | 20 | 6.0 |
Antigens, CD/analysis/*metabolism | 2 | 13.0 |
Asthma/*immunology | 4 | 4.0 |
Hypersensitivity, Immediate/*immunology | 2 | 7.0 |
CD4-Positive T-Lymphocytes/*cytology/*immunology | 2 | 22.0 |
Cell Movement/immunology | 4 | 4.0 |
Cell Separation/methods | 4 | 2.0 |
Fluorescent Dyes | 5 | 1.0 |
Graft Rejection/immunology | 2 | 3.0 |
Transplantation, Homologous/immunology | 2 | 4.0 |
Antibodies, Bispecific/immunology/*pharmacology | 2 | 66.0 |
Antigens, CD/metabolism | 29 | 3.0 |
Antigens, CD19/*immunology | 6 | 19.0 |
Antigens, CD28/*immunology | 124 | 90.0 |
Antigens, CD3/*immunology | 35 | 33.0 |
Antigens, CD80/metabolism | 27 | 33.0 |
*Cytotoxicity, Immunologic | 25 | 5.0 |
Immunotherapy | 11 | 3.0 |
Membrane Glycoproteins/metabolism | 26 | 4.0 |
Recombinant Proteins/immunology | 5 | 1.0 |
Antigens, CD/immunology | 55 | 11.0 |
Antigens, CD40/immunology | 8 | 15.0 |
Antigens, CD80/immunology | 29 | 44.0 |
CD40 Ligand/immunology | 4 | 36.0 |
Clonal Deletion | 3 | 23.0 |
*Immune Tolerance | 17 | 10.0 |
Immunosuppression/*methods | 2 | 8.0 |
Membrane Glycoproteins/immunology | 20 | 10.0 |
*Models, Immunological | 6 | 14.0 |
T-Lymphocyte Subsets/drug effects/immunology | 2 | 10.0 |
Transplantation, Homologous/*immunology | 3 | 11.0 |
Antigens, Differentiation/metabolism | 20 | 16.0 |
Models, Immunological | 20 | 9.0 |
T-Lymphocytes/cytology/immunology | 3 | 4.0 |
Amino Acid Sequence | 121 | 0.0 |
Carrier Proteins/*immunology | 4 | 8.0 |
Models, Molecular | 9 | 0.0 |
Mutagenesis | 6 | 0.0 |
*Proteins | 3 | 0.0 |
Sequence Homology, Amino Acid | 28 | 0.0 |
Cell Survival | 17 | 1.0 |
Immunotherapy, Adoptive/*methods | 7 | 17.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Mice, Inbred NOD | 5 | 2.0 |
Mice, SCID | 24 | 3.0 |
Proto-Oncogene Proteins c-bcl-2/*genetics | 2 | 2.0 |
Retroviridae/genetics | 6 | 1.0 |
Transduction, Genetic/*methods | 2 | 11.0 |
Antigens, CD/biosynthesis/*physiology | 2 | 6.0 |
Antigens, CD80/biosynthesis | 11 | 20.0 |
Cell Membrane/immunology/metabolism | 10 | 9.0 |
Cytotoxicity Tests, Immunologic | 8 | 1.0 |
Immunity, Cellular/genetics | 2 | 18.0 |
Killer Cells, Natural/*immunology | 14 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 77 | 0.0 |
Swine | 5 | 0.0 |
Transduction, Genetic | 6 | 1.0 |
Autoimmune Diseases/immunology | 3 | 3.0 |
DNA, Complementary/genetics | 5 | 0.0 |
Graft Rejection/*immunology | 4 | 5.0 |
Kidney Transplantation/*immunology | 5 | 2.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/physiology | 2 | 15.0 |
Androstadienes/pharmacology | 11 | 4.0 |
Antigens, CD2/*physiology | 7 | 28.0 |
Cell Cycle | 10 | 0.0 |
Cell Division/physiology | 15 | 1.0 |
Enzyme Induction | 5 | 0.0 |
Receptors, Antigen, T-Cell/immunology | 32 | 16.0 |
Signal Transduction/drug effects | 11 | 1.0 |
Thionucleotides/pharmacology | 2 | 3.0 |
Antigens, CD28/immunology | 103 | 70.0 |
Antigens, Differentiation/immunology | 26 | 24.0 |
Autoimmunity | 7 | 5.0 |
Interleukin-13/biosynthesis | 2 | 11.0 |
Signal Transduction/*immunology | 56 | 14.0 |
T-Lymphocytes/cytology/drug effects/*immunology | 4 | 14.0 |
*Antigens, CD3 | 4 | 21.0 |
Apoptosis/immunology | 10 | 10.0 |
Biological Markers/analysis | 13 | 1.0 |
Blotting, Western | 19 | 0.0 |
Clone Cells | 54 | 5.0 |
Exocytosis/*immunology | 2 | 66.0 |
Membrane Proteins/*metabolism | 6 | 1.0 |
Microscopy, Immunoelectron | 3 | 0.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*metabolism | 8 | 50.0 |
T-Lymphocytes/*immunology/metabolism/ultrastructure | 2 | 50.0 |
Antigens, Differentiation/*metabolism | 24 | 19.0 |
Receptors, Antigen, T-Cell/metabolism | 31 | 18.0 |
Alleles | 16 | 0.0 |
Antigens, CD28/genetics | 11 | 57.0 |
Antigens, Differentiation/genetics | 6 | 19.0 |
Antigens, Differentiation, T-Lymphocyte/*genetics | 12 | 22.0 |
Chromosomes, Human, Pair 2/genetics | 3 | 2.0 |
Exons | 7 | 0.0 |
Finland | 2 | 0.0 |
Gene Frequency | 15 | 0.0 |
Linkage (Genetics) | 8 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Apoptosis/*drug effects | 4 | 0.0 |
Cyclosporine/*pharmacology | 11 | 10.0 |
T-Lymphocytes/*drug effects | 5 | 7.0 |
DNA/metabolism | 7 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Down-Regulation | 29 | 1.0 |
Enhancer Elements (Genetics) | 7 | 1.0 |
Genes, Reporter | 14 | 0.0 |
Interleukin-2/metabolism | 19 | 13.0 |
Luciferases/metabolism | 4 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 5 | 3.0 |
Mutation | 20 | 0.0 |
NF-kappa B/metabolism | 20 | 2.0 |
Plasmids/metabolism | 4 | 0.0 |
Proto-Oncogene Proteins c-jun/metabolism | 6 | 4.0 |
Proto-Oncogene Proteins c-rel/metabolism | 2 | 20.0 |
T-Lymphocytes/*enzymology | 4 | 6.0 |
Transcription, Genetic | 35 | 0.0 |
Antigens, CD80/*immunology | 27 | 54.0 |
Carcinoembryonic Antigen/*immunology | 3 | 16.0 |
Colonic Neoplasms/*immunology | 3 | 12.0 |
DNA Primers | 22 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 27 | 0.0 |
Gene Therapy | 2 | 0.0 |
Lymphocytes, Tumor-Infiltrating/*immunology | 8 | 11.0 |
Recombinant Fusion Proteins/*immunology | 2 | 9.0 |
Antigens, CD28/analysis | 26 | 70.0 |
Antigens, Differentiation, T-Lymphocyte/analysis | 10 | 2.0 |
*Cell Communication | 8 | 9.0 |
Interferon Type II/physiology | 3 | 3.0 |
Membrane Glycoproteins/analysis | 9 | 3.0 |
Disease-Free Survival | 2 | 0.0 |
Immune Tolerance/immunology | 7 | 14.0 |
Lymph Nodes/immunology/pathology | 2 | 4.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Phenotype | 78 | 0.0 |
Postoperative Complications | 2 | 1.0 |
Prognosis | 8 | 0.0 |
Prospective Studies | 11 | 0.0 |
Receptors, Cell Surface/*immunology | 2 | 2.0 |
Thymidine/metabolism | 2 | 0.0 |
Adjuvants, Immunologic/*pharmacology | 7 | 4.0 |
Antigens, CD4/metabolism | 8 | 2.0 |
CD4-Positive T-Lymphocytes/cytology/drug effects/*immunology | 3 | 23.0 |
Clonal Anergy | 19 | 51.0 |
Solubility | 18 | 1.0 |
Antigens, CD28/*biosynthesis | 16 | 94.0 |
English Abstract | 27 | 0.0 |
Cell Cycle/immunology | 6 | 18.0 |
Cyclins/biosynthesis | 2 | 2.0 |
Down-Regulation/*immunology | 4 | 7.0 |
Lymphocyte Activation/immunology | 73 | 13.0 |
MAP Kinase Kinase 1 | 9 | 5.0 |
MAP Kinase Kinase 2 | 2 | 4.0 |
MAP Kinase Signaling System/immunology | 3 | 15.0 |
Proto-Oncogene Proteins/*metabolism | 15 | 1.0 |
Receptor-CD3 Complex, Antigen, T-Cell/physiology | 9 | 33.0 |
Substrate Specificity/immunology | 2 | 13.0 |
Th1 Cells/immunology/metabolism | 5 | 13.0 |
Th2 Cells/immunology/metabolism | 5 | 12.0 |
Acquired Immunodeficiency Syndrome/etiology/*immunology | 2 | 20.0 |
Antigens, CD28/biosynthesis/*immunology | 3 | 75.0 |
Biological Markers | 24 | 1.0 |
CD4-Positive T-Lymphocytes/*immunology | 76 | 9.0 |
Cross-Sectional Studies | 8 | 0.0 |
HIV Infections/*immunology | 33 | 7.0 |
Predictive Value of Tests | 8 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 19 | 3.0 |
Sequence Deletion | 8 | 0.0 |
*Signal Transduction | 37 | 1.0 |
Antigens, CD4/immunology | 5 | 2.0 |
Antigens, Differentiation/*biosynthesis | 5 | 15.0 |
CD4 Lymphocyte Count | 23 | 1.0 |
CD4-Positive T-Lymphocytes/cytology/immunology | 5 | 9.0 |
Clonal Anergy/*immunology | 6 | 25.0 |
Ki-67 Antigen/biosynthesis | 2 | 2.0 |
Leukocytes, Mononuclear/cytology/immunology | 5 | 11.0 |
Receptors, CCR5/biosynthesis | 4 | 10.0 |
Receptors, Interleukin-2/biosynthesis | 19 | 17.0 |
*Up-Regulation | 7 | 2.0 |
T-Lymphocyte Subsets/immunology | 32 | 8.0 |
Membrane Microdomains/immunology | 2 | 40.0 |
Transcription Factor AP-1/metabolism | 6 | 2.0 |
ras Proteins/metabolism | 3 | 1.0 |
Antigens, CD/*metabolism | 34 | 5.0 |
Antigens, CD80/*metabolism | 28 | 49.0 |
Antigens, Differentiation, T-Lymphocyte/metabolism | 12 | 10.0 |
Antigens, Surface/metabolism | 3 | 2.0 |
Autoimmune Diseases/etiology | 2 | 11.0 |
*Blood Proteins | 3 | 3.0 |
Membrane Glycoproteins/*metabolism | 27 | 5.0 |
Peptides/metabolism | 3 | 1.0 |
Antigen-Presenting Cells/physiology | 15 | 27.0 |
Interferon Type II/metabolism | 10 | 4.0 |
Lymphocyte Activation/*physiology | 22 | 26.0 |
Nickel/*immunology | 2 | 28.0 |
Up-Regulation | 29 | 1.0 |
Antibodies, Monoclonal/*immunology | 26 | 3.0 |
Cloning, Molecular | 39 | 0.0 |
Gene Expression Regulation/immunology | 9 | 5.0 |
Species Specificity | 13 | 0.0 |
Antigen-Presenting Cells/metabolism | 4 | 22.0 |
Antigens, CD/*analysis | 24 | 3.0 |
HLA-DR Antigens/metabolism | 8 | 5.0 |
Integrins/analysis | 2 | 4.0 |
Interferon Type II/pharmacology | 16 | 2.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Receptors, Interleukin/analysis | 2 | 18.0 |
Antigen-Presenting Cells/*immunology | 23 | 15.0 |
CD8-Positive T-Lymphocytes/metabolism | 14 | 18.0 |
Cell Separation | 25 | 2.0 |
Coculture Techniques | 20 | 2.0 |
Immunotherapy, Adoptive/methods | 3 | 25.0 |
K562 Cells | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 28 | 0.0 |
T-Lymphocytes, Cytotoxic/*cytology/*immunology | 2 | 50.0 |
CD4-Positive T-Lymphocytes/immunology/*metabolism | 6 | 17.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis | 2 | 5.0 |
Interleukin-4/biosynthesis | 15 | 10.0 |
Lymphocyte Activation/*drug effects/immunology | 4 | 18.0 |
Hydrogen Peroxide/pharmacology | 3 | 1.0 |
Lymphocyte Activation/physiology | 11 | 16.0 |
Necrosis | 3 | 0.0 |
Reactive Oxygen Species/metabolism | 2 | 0.0 |
T-Lymphocytes/cytology/immunology/*metabolism | 4 | 30.0 |
*Cell Cycle Proteins | 16 | 1.0 |
Luciferases/genetics | 4 | 1.0 |
NF-kappa B/*metabolism | 14 | 2.0 |
Protein-Serine-Threonine Kinases/*metabolism | 12 | 1.0 |
Inflammation/*physiopathology | 3 | 5.0 |
Models, Biological | 28 | 0.0 |
Recombinant Proteins/therapeutic use | 2 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Hela Cells | 7 | 0.0 |
Histocompatibility Antigens Class I/analysis | 3 | 3.0 |
Histocompatibility Antigens Class II/analysis | 7 | 3.0 |
Macaca mulatta | 4 | 0.0 |
Virus Replication | 11 | 1.0 |
Biological Transport | 5 | 0.0 |
Models, Chemical | 2 | 0.0 |
Regression Analysis | 4 | 0.0 |
Antibodies/immunology | 6 | 1.0 |
Apoptosis/physiology | 4 | 1.0 |
CD4-Positive T-Lymphocytes/*metabolism | 12 | 13.0 |
Interleukin-4/metabolism | 5 | 5.0 |
Receptors, Interleukin-2/*metabolism | 5 | 6.0 |
Adjuvants, Immunologic/*physiology | 5 | 16.0 |
Antigens, Differentiation/*immunology | 21 | 15.0 |
Islets of Langerhans Transplantation/*immunology | 2 | 22.0 |
Antigen-Presenting Cells/immunology | 43 | 15.0 |
Autoimmune Diseases/therapy | 2 | 20.0 |
Cancer Vaccines | 2 | 18.0 |
Dendritic Cells/immunology | 13 | 9.0 |
Major Histocompatibility Complex/physiology | 4 | 25.0 |
Peptides/physiology | 3 | 8.0 |
Receptors, Antigen, T-Cell/physiology | 36 | 25.0 |
Lymphocyte Activation/*drug effects | 36 | 10.0 |
T-Lymphocytes/*drug effects/immunology | 11 | 12.0 |
Tuberculin/immunology/pharmacology | 2 | 66.0 |
Kidney Transplantation/immunology | 4 | 7.0 |
Lymphocyte Depletion | 3 | 1.0 |
Cell Membrane/metabolism | 8 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Fluorescent Antibody Technique | 10 | 0.0 |
Precipitin Tests | 19 | 0.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Clonal Anergy/immunology | 4 | 28.0 |
Dendritic Cells/*immunology | 11 | 4.0 |
Immune Tolerance/*immunology | 5 | 10.0 |
Interleukin-2/pharmacology | 38 | 6.0 |
Phosphoprotein Phosphatase/*physiology | 2 | 15.0 |
T-Lymphocytes/*metabolism | 43 | 11.0 |
Antigens, CD4/biosynthesis | 7 | 8.0 |
Antigens, CD8/biosynthesis | 5 | 14.0 |
Apoptosis/*immunology | 19 | 10.0 |
CD4-Positive T-Lymphocytes/immunology | 60 | 7.0 |
CD8-Positive T-Lymphocytes/immunology | 37 | 7.0 |
Cell Aging | 6 | 6.0 |
Longitudinal Studies | 7 | 0.0 |
Receptors, Interleukin-2/*biosynthesis | 2 | 5.0 |
Staining and Labeling | 2 | 0.0 |
Staphylococcus aureus | 3 | 4.0 |
Antigens, CD28 | 123 | 86.0 |
Antigens, CD3 | 51 | 11.0 |
Antigens, CD4 | 3 | 3.0 |
Antigens, CD8 | 5 | 1.0 |
*Receptors, Antigen, T-Cell, alpha-beta | 2 | 50.0 |
T-Lymphocytes/*cytology/immunology | 4 | 8.0 |
Half-Life | 2 | 0.0 |
Carcinoma, Renal Cell/*immunology | 3 | 16.0 |
*Immunization | 2 | 4.0 |
Kidney Neoplasms/*immunology | 3 | 11.0 |
Tumor Necrosis Factor-alpha/pharmacology | 10 | 0.0 |
Child, Preschool | 33 | 0.0 |
Chromosome Mapping | 14 | 0.0 |
CD4-Positive T-Lymphocytes/immunology/metabolism | 8 | 11.0 |
Carrier Proteins/metabolism | 6 | 0.0 |
Gene Expression Regulation/physiology | 6 | 2.0 |
Jurkat Cells/immunology | 4 | 66.0 |
Macromolecular Substances | 14 | 0.0 |
*Membrane Proteins | 5 | 0.0 |
Phosphotyrosine/chemistry | 2 | 15.0 |
Protein Processing, Post-Translational | 5 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 22 | 2.0 |
Receptors, Antigen, T-Cell/*immunology | 31 | 17.0 |
Recombinant Fusion Proteins/immunology | 5 | 4.0 |
Signal Transduction/*physiology | 19 | 1.0 |
Actins/metabolism | 2 | 0.0 |
Amino Acid Motifs | 6 | 0.0 |
Antigens, CD80/genetics/immunology | 4 | 33.0 |
COS Cells | 10 | 0.0 |
Cercopithecus aethiops | 6 | 0.0 |
Cricetulus | 6 | 1.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Interleukin-2/*biosynthesis/genetics | 6 | 33.0 |
Interleukin-4/*biosynthesis/genetics | 3 | 50.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Transcription, Genetic/*physiology | 2 | 1.0 |
Gene Transfer Techniques | 6 | 1.0 |
Recombinant Fusion Proteins/metabolism | 10 | 0.0 |
T-Lymphocytes/*cytology | 5 | 5.0 |
*Signal Transduction/immunology | 2 | 28.0 |
G(M1) Ganglioside/metabolism | 2 | 10.0 |
Analysis of Variance | 4 | 0.0 |
Chi-Square Distribution | 2 | 0.0 |
Risk Factors | 8 | 0.0 |
Allergens/*immunology | 9 | 11.0 |
Antigens, CD80/*physiology | 33 | 66.0 |
Bronchi/*immunology | 2 | 20.0 |
Mucous Membrane/immunology | 3 | 11.0 |
Antigens, CD80/*chemistry/*metabolism | 3 | 100.0 |
Cell Adhesion | 18 | 1.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
*Chromosomes, Human, Pair 2 | 5 | 1.0 |
Microsatellite Repeats/genetics | 4 | 1.0 |
*Multigene Family | 3 | 0.0 |
Open Reading Frames | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Antigens, CD/drug effects/immunology | 2 | 40.0 |
Antigens, CD28/drug effects/immunology | 2 | 100.0 |
B-Lymphocytes/drug effects/immunology | 4 | 13.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology/secretion | 2 | 50.0 |
Up-Regulation/drug effects/immunology | 2 | 5.0 |
Antigens, CD/*biosynthesis | 11 | 5.0 |
Membrane Glycoproteins/*biosynthesis | 5 | 5.0 |
T-Lymphocytes/cytology/immunology/metabolism | 4 | 20.0 |
Tetanus Toxoid/immunology | 7 | 8.0 |
Up-Regulation/*immunology | 12 | 22.0 |
Antigen Presentation/physiology | 3 | 25.0 |
Up-Regulation/physiology | 3 | 2.0 |
Antigens, CD28/chemistry/genetics/*metabolism | 3 | 100.0 |
Antigens, Differentiation/chemistry/genetics/metabolism | 2 | 66.0 |
Lymphocyte Activation/drug effects/*immunology | 10 | 23.0 |
Serine Endopeptidases/metabolism | 4 | 3.0 |
Combined Modality Therapy | 2 | 0.0 |
*Immunotherapy | 10 | 6.0 |
*Chromosome Mapping | 6 | 0.0 |
Immunosuppressive Agents | 2 | 16.0 |
Antigens, CD28/genetics/*physiology | 6 | 100.0 |
Interleukin-2/*secretion | 6 | 40.0 |
Lymphocyte Activation/*genetics | 7 | 28.0 |
Receptors, IgG/genetics | 4 | 23.0 |
T-Lymphocytes/*immunology/metabolism/secretion | 2 | 100.0 |
Antigens, CD28/chemistry/*metabolism | 5 | 100.0 |
Antigens, CD80/genetics/*metabolism | 6 | 42.0 |
Histocompatibility Antigens Class II/metabolism | 6 | 7.0 |
Intercellular Adhesion Molecule-1/metabolism | 7 | 3.0 |
*Alternative Splicing | 2 | 0.0 |
Antigens, CD28/biosynthesis/*genetics | 2 | 100.0 |
Leukocytes, Mononuclear/drug effects/*immunology | 2 | 6.0 |
Antigens, CD/*immunology | 50 | 10.0 |
Antigens, CD80/*analysis | 6 | 40.0 |
Cell Count | 6 | 0.0 |
Conjunctivitis, Allergic/*immunology | 2 | 25.0 |
Immunohistochemistry | 32 | 0.0 |
Langerhans Cells/*immunology | 2 | 5.0 |
Membrane Glycoproteins/*immunology | 14 | 7.0 |
Statistics, Nonparametric | 8 | 0.0 |
Antigens, CD57/analysis | 4 | 9.0 |
Antigens, CD8/analysis | 14 | 5.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 4 | 5.0 |
Receptors, Antigen, T-Cell, alpha-beta/analysis | 2 | 4.0 |
Serine Endopeptidases/analysis | 2 | 5.0 |
T-Lymphocytes, Suppressor-Effector/*immunology | 5 | 5.0 |
CD8-Positive T-Lymphocytes/classification/*immunology | 4 | 80.0 |
T-Lymphocytes/classification/*immunology | 4 | 6.0 |
CD4-Positive T-Lymphocytes/*enzymology | 2 | 40.0 |
Cercocebus atys | 2 | 33.0 |
Protein-Tyrosine Kinase/genetics/*metabolism | 2 | 1.0 |
Diabetes Mellitus, Type 1/*genetics | 5 | 2.0 |
Haplotypes | 4 | 0.0 |
Japan | 4 | 0.0 |
Linkage Disequilibrium | 3 | 0.0 |
*Polymorphism, Genetic | 13 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 31 | 13.0 |
Acquired Immunodeficiency Syndrome/*drug therapy/immunology | 2 | 4.0 |
*Antiretroviral Therapy, Highly Active | 5 | 1.0 |
CD4-Positive T-Lymphocytes/*physiology | 7 | 8.0 |
CD8-Positive T-Lymphocytes/*physiology | 2 | 11.0 |
*HIV-1 | 15 | 1.0 |
Membrane Glycoproteins/*analysis | 11 | 7.0 |
Antigens, CD28/genetics/*metabolism | 13 | 92.0 |
B-Lymphocytes/drug effects/*immunology | 3 | 9.0 |
Mitogens/pharmacology | 12 | 4.0 |
Antigens, CD57/metabolism | 3 | 30.0 |
CD4-CD8 Ratio | 20 | 3.0 |
CD8-Positive T-Lymphocytes/enzymology/immunology | 2 | 100.0 |
Killer Cells, Natural/immunology | 12 | 2.0 |
Leukemia, B-Cell, Chronic/*immunology | 3 | 6.0 |
Exons/genetics | 3 | 0.0 |
Lupus Erythematosus, Systemic/*genetics | 2 | 3.0 |
Promoter Regions (Genetics)/*genetics | 4 | 0.0 |
CD4-Positive T-Lymphocytes/metabolism | 17 | 13.0 |
*Gene Expression Regulation | 15 | 0.0 |
Interleukin-2/*genetics | 19 | 30.0 |
Lymphocyte Function-Associated Antigen-1/*physiology | 3 | 7.0 |
Administration, Oral | 2 | 0.0 |
Histocompatibility Antigens Class I/immunology | 4 | 3.0 |
Vaccination | 3 | 1.0 |
Chemokines, CC/immunology | 3 | 20.0 |
Cytokines/immunology | 7 | 4.0 |
Oxidation-Reduction | 2 | 0.0 |
Immunoglobulins/genetics | 3 | 7.0 |
Interferon Type II/biosynthesis/genetics | 6 | 16.0 |
Myelin Basic Proteins/immunology | 5 | 5.0 |
RNA, Messenger/genetics/metabolism | 16 | 0.0 |
Antibodies, Monoclonal | 53 | 2.0 |
Antigens, CD28/*genetics/immunology | 4 | 100.0 |
Antigens, CD80/*genetics | 4 | 13.0 |
Multiple Myeloma/*immunology/pathology | 2 | 11.0 |
Antigens, CD40/analysis | 3 | 12.0 |
Antigens, CD80/analysis | 7 | 14.0 |
Lymphatic Metastasis | 2 | 0.0 |
*Adaptor Protein Complex 2 | 3 | 42.0 |
*Adaptor Protein Complex mu Subunits | 3 | 37.0 |
Adaptor Proteins, Vesicular Transport | 5 | 7.0 |
Amino Acid Substitution | 2 | 0.0 |
Clathrin/*metabolism | 2 | 5.0 |
DNA Primers/genetics | 9 | 0.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Immunosuppressive Agents/therapeutic use | 5 | 2.0 |
*Desensitization, Immunologic | 4 | 14.0 |
Interleukin-10/*physiology | 3 | 15.0 |
Immunity, Cellular | 17 | 2.0 |
Wegener's Granulomatosis/*immunology | 2 | 18.0 |
CD4-Positive T-Lymphocytes/*immunology/*virology | 2 | 13.0 |
Flow Cytometry/methods | 9 | 3.0 |
Muromonab-CD3/immunology | 3 | 30.0 |
*Virus Replication | 4 | 1.0 |
Cell Cycle Proteins/metabolism | 4 | 1.0 |
*Clonal Anergy | 11 | 37.0 |
T-Lymphocytes/cytology/*immunology | 20 | 15.0 |
*Tumor Suppressor Proteins | 4 | 0.0 |
Antigens, Surface/*immunology | 9 | 5.0 |
B-Lymphocytes/immunology | 22 | 3.0 |
Glycoproteins/*immunology | 2 | 2.0 |
Macrophages/immunology | 5 | 1.0 |
Rhinitis, Allergic, Perennial/*immunology | 2 | 15.0 |
Antibodies, Monoclonal/pharmacology | 74 | 10.0 |
Antigens, CD3/biosynthesis | 7 | 12.0 |
DNA/biosynthesis | 8 | 1.0 |
Phytohemagglutinins/pharmacology | 30 | 5.0 |
Telomerase/*metabolism | 4 | 9.0 |
CD4-Positive T-Lymphocytes/drug effects/immunology | 4 | 9.0 |
CD8-Positive T-Lymphocytes/drug effects/immunology | 2 | 8.0 |
Double-Blind Method | 2 | 0.0 |
Exercise/*physiology | 2 | 0.0 |
Killer Cells, Natural/drug effects/immunology | 2 | 6.0 |
Monocytes/cytology | 2 | 1.0 |
Age Factors | 7 | 0.0 |
Disease Transmission, Vertical | 2 | 2.0 |
HIV Infections/*immunology/*transmission | 2 | 33.0 |
Antigens, CD28/*biosynthesis/genetics | 4 | 100.0 |
Cell-Free System | 2 | 0.0 |
Promoter Regions (Genetics)/drug effects | 3 | 2.0 |
RNA, Messenger/biosynthesis/genetics | 5 | 0.0 |
Transcription, Genetic/drug effects | 9 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Antigens, CD3/physiology | 31 | 41.0 |
H-2 Antigens/*immunology | 2 | 13.0 |
Mast-Cell Sarcoma/pathology | 2 | 22.0 |
T-Lymphocyte Subsets/*enzymology | 2 | 50.0 |
Isoenzymes/biosynthesis | 2 | 4.0 |
Neoplasms, Experimental/*immunology | 3 | 25.0 |
Cell Movement | 10 | 1.0 |
Disease Progression | 16 | 0.0 |
Receptors, Immunologic/metabolism | 5 | 3.0 |
T-Lymphocytes, Cytotoxic/*immunology | 33 | 6.0 |
Cytomegalovirus/*immunology | 3 | 4.0 |
Immunologic Memory | 32 | 10.0 |
Protein Conformation | 8 | 0.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 2 | 2.0 |
T-Lymphocytes, Cytotoxic | 2 | 9.0 |
Antigens, CD28/biosynthesis/immunology | 3 | 75.0 |
Antigens, CD80/biosynthesis/immunology | 2 | 50.0 |
Antigens, Differentiation/biosynthesis/immunology | 2 | 50.0 |
Immunophenotyping/methods | 2 | 4.0 |
Membrane Glycoproteins/biosynthesis/immunology | 3 | 25.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 4 | 1.0 |
Membrane Proteins/metabolism | 12 | 2.0 |
Protein Transport | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 5 | 0.0 |
Carrier Proteins/*metabolism | 5 | 0.0 |
Cytomegalovirus/immunology | 7 | 10.0 |
Histocompatibility Antigens Class I/*metabolism | 7 | 7.0 |
Receptors, Immunologic/*metabolism | 5 | 2.0 |
Viral Proteins/immunology | 2 | 6.0 |
Antigens, CD/*immunology/metabolism | 5 | 15.0 |
*Clonal Anergy/drug effects | 2 | 100.0 |
Fetal Blood/cytology/immunology | 2 | 5.0 |
Infant, Newborn | 27 | 0.0 |
Interleukin-10/pharmacology | 5 | 7.0 |
Interleukin-2/biosynthesis/pharmacology | 2 | 9.0 |
Interleukin-4/pharmacology | 15 | 4.0 |
Inositol Phosphates/metabolism | 2 | 1.0 |
Phosphatidylinositols/*metabolism | 3 | 3.0 |
Cytokines/secretion | 8 | 10.0 |
Interleukins/biosynthesis | 4 | 9.0 |
Killer Cells, Natural/drug effects/*immunology | 2 | 5.0 |
ADP-ribosyl Cyclase | 14 | 3.0 |
Antigens, CD57 | 5 | 7.0 |
Antigens, Differentiation | 2 | 2.0 |
Cohort Studies | 6 | 0.0 |
*HIV Long-Term Survivors | 2 | 10.0 |
Infant | 23 | 0.0 |
Viral Load | 13 | 1.0 |
Antigens, CD4/*metabolism | 5 | 1.0 |
*Immunophenotyping | 6 | 3.0 |
T-Lymphocyte Subsets/*immunology | 57 | 10.0 |
Adoptive Transfer | 3 | 3.0 |
Autoantigens/immunology | 3 | 2.0 |
Incidence | 2 | 0.0 |
Rats, Inbred Lew | 7 | 2.0 |
Tumor Necrosis Factor-alpha/biosynthesis | 11 | 2.0 |
Cell Line, Tumor | 6 | 0.0 |
T-Lymphocytes/chemistry/*immunology/metabolism | 2 | 66.0 |
Antibodies, Viral/immunology | 2 | 2.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
RNA, Viral/blood | 8 | 1.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics | 4 | 5.0 |
Antigens, CD45/biosynthesis | 7 | 13.0 |
*Antigens, CD80 | 4 | 66.0 |
Antigens, Differentiation/physiology | 14 | 26.0 |
CD4-Positive T-Lymphocytes/*immunology/metabolism | 4 | 7.0 |
HLA-DR Antigens/biosynthesis | 7 | 7.0 |
Immunosuppressive Agents/pharmacology | 19 | 11.0 |
RNA, Messenger/antagonists & inhibitors/metabolism | 2 | 13.0 |
Receptors, Antigen, T-Cell/immunology/metabolism/physiology | 2 | 100.0 |
T-Lymphocyte Subsets/*immunology/metabolism | 14 | 31.0 |
Cross-Linking Reagents | 24 | 6.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Down-Regulation/drug effects | 3 | 1.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 94 | 5.0 |
Lectins | 2 | 2.0 |
Lymphoma, Non-Hodgkin/pathology | 2 | 14.0 |
Multigene Family | 4 | 0.0 |
Receptors, Immunologic/physiology | 13 | 11.0 |
Tumor Necrosis Factor-alpha/physiology | 2 | 1.0 |
Culture Media, Conditioned | 3 | 0.0 |
Phytohemagglutinins/immunology | 4 | 8.0 |
Antigens, CD95/biosynthesis | 3 | 10.0 |
Antigens, Differentiation/biosynthesis | 8 | 15.0 |
HIV Seropositivity/*immunology | 2 | 2.0 |
Antigens/*immunology | 3 | 3.0 |
Antigens, CD28/metabolism/*physiology | 3 | 100.0 |
Antigens, CD80/metabolism/physiology | 3 | 75.0 |
DNA-Binding Proteins/physiology | 10 | 3.0 |
Enhancer Elements (Genetics)/immunology | 3 | 25.0 |
Mitogen-Activated Protein Kinase Kinases | 2 | 5.0 |
Proto-Oncogene Proteins/metabolism/*physiology | 2 | 4.0 |
Trans-Activation (Genetics)/immunology | 4 | 16.0 |
Transcription Factors/physiology | 4 | 1.0 |
Antigens, CD28/*analysis | 15 | 78.0 |
CD4-Positive T-Lymphocytes/*cytology | 2 | 4.0 |
Transplantation, Homologous | 9 | 1.0 |
src-Family Kinases/metabolism | 3 | 1.0 |
Cell Adhesion Molecules/immunology | 6 | 8.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*immunology | 3 | 16.0 |
Immunoglobulin E/biosynthesis | 4 | 10.0 |
Lung/*immunology | 4 | 9.0 |
Th1 Cells/*immunology | 9 | 6.0 |
Antigens, CD28/drug effects | 2 | 100.0 |
Graft Rejection/drug therapy/immunology | 3 | 50.0 |
Transplantation Tolerance/*immunology | 2 | 25.0 |
Crohn Disease/genetics/*immunology/pathology | 2 | 66.0 |
Receptors, Antigen, T-Cell, alpha-beta/biosynthesis | 3 | 13.0 |
Antigens, CD28/*metabolism/*pharmacology | 2 | 100.0 |
B-Lymphocytes/drug effects/metabolism | 2 | 9.0 |
Interleukin-8/*biosynthesis/genetics | 3 | 7.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
DNA, Complementary | 7 | 0.0 |
*Enhancer Elements (Genetics) | 4 | 1.0 |
Receptor-CD3 Complex, Antigen, T-Cell/metabolism | 4 | 36.0 |
Receptors, Interleukin-2/*genetics | 2 | 7.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
*Trans-Activation (Genetics) | 3 | 0.0 |
Transcription Factor AP-1/*metabolism | 5 | 3.0 |
Hypersensitivity/immunology | 2 | 5.0 |
Cytokines/blood | 4 | 1.0 |
Immunoglobulin E/*blood | 2 | 3.0 |
Antigens, CD45/analysis | 20 | 7.0 |
CD4-Positive T-Lymphocytes/chemistry | 3 | 16.0 |
Receptors, Antigen, T-Cell/analysis | 4 | 3.0 |
Receptors, Interleukin-2/analysis | 14 | 5.0 |
Bronchoalveolar Lavage Fluid/cytology/immunology | 2 | 5.0 |
Receptors, Antigen, T-Cell/*genetics/immunology | 2 | 22.0 |
Sarcoidosis, Pulmonary/*immunology | 3 | 17.0 |
Antigens, CD/biosynthesis | 23 | 7.0 |
Antibodies, Monoclonal/immunology/pharmacology | 7 | 7.0 |
Antigens, CD95/immunology | 2 | 3.0 |
In Situ Hybridization, Fluorescence | 6 | 0.0 |
Epitopes | 12 | 1.0 |
Keratinocytes/immunology | 2 | 8.0 |
RNA, Messenger/metabolism | 22 | 0.0 |
T-Lymphocytes/*immunology/metabolism | 29 | 18.0 |
Transforming Growth Factor beta/genetics | 2 | 2.0 |
Antigens, CD45/*metabolism | 4 | 12.0 |
Histocompatibility Antigens Class II/*metabolism | 3 | 5.0 |
Virion/*metabolism | 2 | 9.0 |
Antigens, CD3/*physiology | 8 | 47.0 |
Histocompatibility Antigens Class I/physiology | 3 | 13.0 |
Transforming Growth Factor beta/physiology | 2 | 2.0 |
Cyclosporine/pharmacology | 42 | 19.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Interleukin-2/*biosynthesis | 22 | 15.0 |
Ionomycin/pharmacology | 22 | 9.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors | 3 | 1.0 |
Quinones/pharmacology | 11 | 8.0 |
DNA/*analysis | 2 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Antigens, CD45/immunology | 8 | 12.0 |
Antigens, CD57/immunology | 3 | 37.0 |
HIV Infections/drug therapy/*immunology | 5 | 7.0 |
L-Selectin/immunology | 3 | 37.0 |
Exons/*immunology | 2 | 40.0 |
Gene Expression Regulation/*immunology | 9 | 8.0 |
Guanosine/metabolism | 2 | 40.0 |
Mutagenesis, Insertional | 3 | 1.0 |
Promoter Regions (Genetics)/*immunology | 10 | 23.0 |
Cell Membrane/immunology | 6 | 2.0 |
Immunotherapy, Adoptive | 5 | 7.0 |
Recombinant Fusion Proteins/immunology/metabolism | 4 | 19.0 |
Antigens, Differentiation/analysis | 14 | 4.0 |
Cytokines/analysis | 4 | 5.0 |
Immunoenzyme Techniques | 8 | 0.0 |
Macrophages/pathology | 2 | 1.0 |
Periodontitis/*immunology/pathology | 2 | 28.0 |
T-Lymphocytes/pathology | 2 | 1.0 |
United States | 2 | 0.0 |
Trans-Activators/*metabolism | 3 | 0.0 |
Antigens, Differentiation/*physiology | 16 | 18.0 |
Homeostasis | 6 | 1.0 |
Antigens, CD/*physiology | 44 | 14.0 |
Lymphokines/biosynthesis | 6 | 5.0 |
Membrane Glycoproteins/*physiology | 13 | 4.0 |
Th1 Cells/*physiology | 3 | 17.0 |
Antigens, CD45/metabolism | 6 | 7.0 |
T-Lymphocyte Subsets/*immunology/pathology | 2 | 9.0 |
Antigens, CD28/*immunology/*metabolism | 3 | 100.0 |
Calcimycin/pharmacology | 8 | 3.0 |
Ionophores/pharmacology | 5 | 3.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Protein Kinase C/*metabolism | 6 | 2.0 |
Proto-Oncogene Proteins/metabolism | 20 | 1.0 |
*Down-Regulation | 8 | 2.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Allergens/immunology | 5 | 7.0 |
Interleukin-10/*pharmacology | 3 | 3.0 |
B-Lymphocytes/*immunology | 30 | 3.0 |
HLA-DR Antigens/analysis | 8 | 1.0 |
Lupus Erythematosus, Systemic/*immunology | 5 | 3.0 |
Cytokines/pharmacology | 7 | 1.0 |
Antigens, CD/biosynthesis/metabolism | 2 | 18.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis | 5 | 6.0 |
Cytokines/*metabolism | 5 | 1.0 |
Immunoglobulins/metabolism | 3 | 2.0 |
Integrin alpha4 | 3 | 7.0 |
Tumor Necrosis Factor-alpha/metabolism | 8 | 1.0 |
Cell Adhesion Molecules/metabolism | 6 | 2.0 |
Cytokines/metabolism | 15 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/metabolism | 3 | 5.0 |
Immunoblotting | 9 | 0.0 |
Interleukin-12/metabolism | 2 | 3.0 |
Lymphocyte Function-Associated Antigen-1/analysis | 5 | 12.0 |
Immunotherapy/methods | 9 | 10.0 |
Receptors, Fc/metabolism | 3 | 6.0 |
Chromosome Banding | 2 | 0.0 |
RNA Splicing | 2 | 0.0 |
Signal Transduction/genetics | 2 | 0.0 |
Clone Cells/drug effects | 2 | 8.0 |
Dermatitis, Atopic/*immunology | 3 | 7.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 9 | 4.0 |
Th2 Cells/immunology | 7 | 4.0 |
Antibody Formation | 12 | 2.0 |
Thyroid Gland/*immunology | 2 | 3.0 |
Cell Division/drug effects/immunology | 6 | 9.0 |
Cytokines/antagonists & inhibitors/biosynthesis | 4 | 23.0 |
Dose-Response Relationship, Immunologic | 18 | 3.0 |
Down-Regulation/immunology | 13 | 13.0 |
T-Lymphocytes, Cytotoxic/cytology/immunology | 2 | 18.0 |
Up-Regulation/immunology | 10 | 6.0 |
T-Lymphocytes/*cytology/metabolism | 2 | 9.0 |
Adaptor Protein Complex alpha Subunits | 2 | 4.0 |
Cytoplasm/metabolism | 7 | 0.0 |
Gene Products, nef/genetics/*metabolism | 2 | 6.0 |
Antigens, CD2/immunology | 10 | 32.0 |
Leukocytes, Mononuclear/immunology | 11 | 4.0 |
Lymphoma, Non-Hodgkin/immunology | 3 | 20.0 |
Receptor-CD3 Complex, Antigen, T-Cell/immunology | 8 | 33.0 |
Receptors, Interleukin-2/immunology | 7 | 11.0 |
Spleen/cytology/immunology | 3 | 4.0 |
Antigens, CD/genetics/immunology | 2 | 10.0 |
Antigens, CD30/immunology | 4 | 80.0 |
Carcinoembryonic Antigen/immunology | 2 | 14.0 |
Cytotoxicity, Immunologic/immunology | 4 | 5.0 |
Interferon Type II/secretion | 13 | 12.0 |
Membrane Glycoproteins/genetics/immunology | 2 | 9.0 |
T-Lymphocytes/*immunology/secretion | 3 | 37.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
T-Lymphocytes/chemistry/*immunology | 2 | 14.0 |
MAP Kinase Kinase Kinase 2 | 2 | 28.0 |
Mitogen-Activated Protein Kinases/*metabolism | 6 | 1.0 |
Immunoglobulins/biosynthesis | 5 | 4.0 |
Lymphocyte Cooperation | 11 | 14.0 |
Proto-Oncogene Proteins c-bcl-2/genetics | 2 | 1.0 |
src Homology Domains | 10 | 1.0 |
Immunoglobulins, Fc/immunology | 2 | 8.0 |
Antibodies, Monoclonal/metabolism/*pharmacology | 2 | 28.0 |
CD8-Positive T-Lymphocytes/immunology/metabolism | 3 | 7.0 |
Interleukin-2/*physiology | 4 | 5.0 |
Interphase/immunology | 7 | 15.0 |
*Membrane Glycoproteins | 7 | 0.0 |
*Protein-Serine-Threonine Kinases | 7 | 0.0 |
Horses | 2 | 1.0 |
Leukocytes, Mononuclear/immunology/physiology | 2 | 66.0 |
Specific Pathogen-Free Organisms | 4 | 4.0 |
Cell Survival/immunology | 6 | 10.0 |
Interleukin-2/genetics/metabolism | 3 | 20.0 |
NF-kappa B/immunology | 2 | 11.0 |
Colony-Forming Units Assay | 2 | 0.0 |
Leukocyte Count | 10 | 0.0 |
Lymphocyte Subsets/cytology | 2 | 11.0 |
Binding Sites/genetics/immunology | 3 | 6.0 |
Protein Binding/genetics/immunology | 8 | 9.0 |
Signal Transduction/*genetics/*immunology | 2 | 22.0 |
Trans-Activation (Genetics)/*immunology | 3 | 15.0 |
*DNA-Binding Proteins | 3 | 0.0 |
Down-Regulation/genetics/*immunology | 2 | 10.0 |
Antigens, CD/metabolism/physiology | 2 | 25.0 |
Antigens, CD28/immunology/metabolism/*physiology | 4 | 100.0 |
Cell Differentiation/immunology | 17 | 5.0 |
Drug Synergism | 20 | 1.0 |
Fetal Blood | 4 | 2.0 |
Immunologic Memory/genetics | 2 | 28.0 |
Antibodies, Bispecific/administration & dosage/*therapeutic use | 2 | 100.0 |
Antigens, CD19/*therapeutic use | 2 | 66.0 |
Antigens, CD28/*therapeutic use | 3 | 100.0 |
Antigens, CD3/*therapeutic use | 2 | 66.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Leukemia, B-Cell/therapy | 2 | 66.0 |
Lymphoma, Follicular/therapy | 2 | 100.0 |
Lymphoma, Mantle-Cell/therapy | 2 | 100.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Lymph Nodes/metabolism | 2 | 3.0 |
Antigens, CD/genetics/*immunology/metabolism | 2 | 50.0 |
Antigens, CD28/genetics/*immunology/metabolism | 6 | 100.0 |
Antigens, CD80/genetics/*immunology/metabolism | 3 | 60.0 |
Membrane Glycoproteins/genetics/*immunology/metabolism | 2 | 28.0 |
Immunization | 7 | 1.0 |
Leprosy/*immunology | 2 | 8.0 |
Monocytes/immunology | 11 | 2.0 |
Mycobacterium leprae/immunology | 2 | 9.0 |
Antigens, CD28/biosynthesis/genetics/*physiology | 3 | 100.0 |
Crosses, Genetic | 3 | 0.0 |
Hybridomas | 10 | 6.0 |
Injections, Intravenous | 3 | 0.0 |
Lymphocyte Activation/genetics | 12 | 12.0 |
Mice, Inbred DBA | 5 | 1.0 |
Antigens, CD/pharmacology | 3 | 33.0 |
Antigens, CD28/*pharmacology | 5 | 83.0 |
Antigens, CD80/*pharmacology | 5 | 83.0 |
Sequence Alignment | 14 | 0.0 |
Receptors, Immunologic/immunology | 14 | 13.0 |
Receptors, Antigen, T-Cell, alpha-beta/*immunology | 5 | 9.0 |
Receptors, Immunologic/*immunology | 6 | 5.0 |
Antigens, CD80/genetics/*immunology | 5 | 27.0 |
Forecasting | 2 | 0.0 |
Antibodies/pharmacology | 17 | 4.0 |
Antigens, CD28/pharmacology | 9 | 90.0 |
Antigens, CD3/immunology/physiology | 3 | 42.0 |
Up-Regulation/drug effects | 5 | 1.0 |
Signal Transduction/genetics/immunology | 8 | 10.0 |
Antigens, CD/*genetics | 6 | 2.0 |
Membrane Glycoproteins/*genetics | 6 | 1.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Variation (Genetics) | 7 | 0.0 |
*Antigen Presentation | 12 | 7.0 |
Antigens, Neoplasm/immunology | 7 | 5.0 |
Chimeric Proteins/immunology | 2 | 6.0 |
Immunoglobulins/genetics/immunology | 2 | 40.0 |
Membrane Proteins/genetics/*immunology | 2 | 15.0 |
Receptors, Antigen, T-Cell/genetics/*immunology | 4 | 25.0 |
Antibody Affinity | 4 | 2.0 |
*Cell Death | 2 | 4.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
T-Lymphocyte Subsets/*cytology/enzymology/*immunology/metabolism | 2 | 100.0 |
Antigen-Presenting Cells/immunology/metabolism | 3 | 14.0 |
Antigens, CD/*biosynthesis/genetics | 6 | 10.0 |
Cell-Free System/immunology | 2 | 11.0 |
Interleukin-2/physiology | 14 | 16.0 |
Protein Binding/immunology | 10 | 5.0 |
Antigens, CD27/analysis | 2 | 11.0 |
Antigens, CD56/analysis | 4 | 6.0 |
HLA-DR Antigens/*analysis | 2 | 1.0 |
CD8-Positive T-Lymphocytes/*immunology/virology | 4 | 22.0 |
Chronic Disease | 16 | 0.0 |
Cytomegalovirus Infections/*immunology | 4 | 18.0 |
Epitopes/immunology | 5 | 0.0 |
Epstein-Barr Virus Infections/*immunology | 3 | 37.0 |
Leukocytes/virology | 2 | 40.0 |
*Promoter Regions (Genetics) | 9 | 0.0 |
Antibody Formation/immunology | 4 | 8.0 |
Antigens, Differentiation/pharmacology | 11 | 52.0 |
Anti-HIV Agents/*therapeutic use | 6 | 1.0 |
Drug Therapy, Combination | 9 | 0.0 |
HIV Infections/drug therapy/*immunology/virology | 5 | 12.0 |
Colon/immunology | 3 | 14.0 |
T-Lymphocytes/*physiology | 34 | 11.0 |
Melanoma/*immunology | 5 | 5.0 |
Receptors, Antigen, T-Cell, alpha-beta/*analysis | 4 | 16.0 |
T-Lymphocytes/*chemistry | 3 | 13.0 |
Protein Kinase C/metabolism | 6 | 1.0 |
Recombinant Proteins/pharmacology | 12 | 0.0 |
Cell Aging/physiology | 4 | 12.0 |
Signal Transduction/physiology | 9 | 0.0 |
Calcium Signaling | 3 | 3.0 |
Interleukin-2/biosynthesis/secretion | 3 | 100.0 |
T-Lymphocytes/immunology/*metabolism | 20 | 21.0 |
Thymoma | 2 | 22.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Antigens, CD58/physiology | 3 | 42.0 |
Base Composition | 2 | 0.0 |
DNA-Binding Proteins/genetics | 6 | 0.0 |
Multigene Family/immunology | 2 | 8.0 |
Transcription Factors/genetics | 4 | 0.0 |
Clonal Anergy/genetics | 2 | 66.0 |
T-Lymphocytes, Helper-Inducer/immunology/metabolism | 2 | 16.0 |
Chemotaxis, Leukocyte/*immunology | 2 | 4.0 |
T-Lymphocyte Subsets/*immunology/*metabolism | 5 | 19.0 |
CD40 Ligand | 26 | 15.0 |
Lymphocytes/immunology | 3 | 0.0 |
Heart Transplantation/*immunology | 5 | 7.0 |
Mice, Inbred Strains | 10 | 1.0 |
Protein Isoforms/physiology | 2 | 5.0 |
Skin Transplantation/immunology | 3 | 12.0 |
Tissue Donors | 4 | 1.0 |
Antigens, CD3/immunology/*physiology | 3 | 50.0 |
Lymphocyte Culture Test, Mixed | 44 | 6.0 |
Antibodies, Bispecific/*therapeutic use | 5 | 50.0 |
*Immunotherapy, Adoptive | 8 | 12.0 |
Interleukin-10/genetics | 2 | 4.0 |
Receptors, Cytokine/genetics | 2 | 6.0 |
Antigens, CD19/analysis | 2 | 2.0 |
Clone Cells/immunology | 10 | 6.0 |
NAD+ Nucleosidase/analysis | 4 | 9.0 |
Antigens, CD/blood | 10 | 4.0 |
Antigens, CD27/physiology | 3 | 60.0 |
Immunosuppressive Agents/*therapeutic use | 3 | 2.0 |
Receptors, Interleukin-2/blood | 2 | 2.0 |
Recurrence | 3 | 0.0 |
Treatment Failure | 3 | 1.0 |
CD8-Positive T-Lymphocytes/cytology/immunology | 3 | 10.0 |
HIV Antigens/*immunology | 2 | 3.0 |
HIV-1/immunology | 4 | 5.0 |
*Immunosuppression | 5 | 6.0 |
Interleukin-2/immunology | 11 | 10.0 |
Monocytes/metabolism | 3 | 0.0 |
*Receptors, Tumor Necrosis Factor | 4 | 10.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology | 11 | 27.0 |
RNA, Viral/analysis | 3 | 1.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*physiology | 2 | 6.0 |
Antigens, CD28/chemistry/*physiology | 2 | 100.0 |
Chromones/pharmacology | 4 | 1.0 |
Morpholines/pharmacology | 4 | 1.0 |
Antigens, CD28/genetics/metabolism/*physiology | 3 | 100.0 |
Fetus | 3 | 0.0 |
Peptide Fragments/genetics/immunology/metabolism | 2 | 25.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Cell Differentiation/genetics/immunology | 2 | 2.0 |
Interleukin-4/biosynthesis/genetics | 3 | 17.0 |
T-Lymphocyte Subsets/cytology/*immunology/metabolism | 2 | 22.0 |
Cytokines | 4 | 3.0 |
Leukocytes, Mononuclear/cytology/drug effects/immunology | 2 | 12.0 |
Tumor Necrosis Factor-alpha/*biosynthesis | 3 | 0.0 |
Antibodies, Blocking/administration & dosage | 2 | 50.0 |
Histocompatibility Testing | 2 | 0.0 |
Immune Sera/administration & dosage | 2 | 18.0 |
Injections, Intraperitoneal | 6 | 4.0 |
Mice, Inbred A | 3 | 5.0 |
Promoter Regions (Genetics)/immunology | 4 | 5.0 |
Receptors, Antigen, T-Cell/*physiology | 24 | 15.0 |
Response Elements/immunology | 2 | 12.0 |
Talin/metabolism | 2 | 28.0 |
Spleen/cytology/immunology/metabolism | 2 | 12.0 |
Antigens, CD40/*immunology | 2 | 5.0 |
Antigens, Differentiation/administration & dosage | 2 | 50.0 |
Genetic Markers/immunology | 2 | 10.0 |
H-2 Antigens/genetics | 2 | 8.0 |
Mice, Inbred C3H | 13 | 2.0 |
Antigens, CD/genetics | 4 | 2.0 |
Biological Markers/*analysis | 2 | 1.0 |
Cyclosporine/therapeutic use | 3 | 4.0 |
Cytokines/genetics | 5 | 4.0 |
Kidney Transplantation/*immunology/pathology | 2 | 11.0 |
Prednisone/therapeutic use | 2 | 1.0 |
Antigens, CD30/*immunology | 4 | 57.0 |
Immunologic Capping | 3 | 6.0 |
Receptors, Antigen, T-Cell, alpha-beta/*biosynthesis | 2 | 28.0 |
CD8-Positive T-Lymphocytes/drug effects | 3 | 15.0 |
B-Lymphocyte Subsets/*immunology | 2 | 2.0 |
Immunoglobulin M/biosynthesis | 3 | 3.0 |
Intestinal Mucosa/immunology | 2 | 3.0 |
Lymphoid Tissue/immunology | 2 | 5.0 |
Antigens, Neoplasm/*immunology | 8 | 4.0 |
CA-15-3 Antigen/*immunology | 2 | 3.0 |
Cancer Vaccines/*immunology | 3 | 5.0 |
Cell Fusion | 4 | 1.0 |
Epitopes, T-Lymphocyte/analysis | 2 | 33.0 |
Lymph Nodes/immunology | 3 | 3.0 |
Adenoviridae/genetics/immunology | 2 | 33.0 |
Chimera | 2 | 1.0 |
Cytoplasm | 2 | 3.0 |
*Genetic Predisposition to Disease | 3 | 0.0 |
Antigens, CD2/*immunology | 6 | 16.0 |
Blotting, Northern | 24 | 0.0 |
*RNA, Small Cytoplasmic | 2 | 7.0 |
Antigens, CD/metabolism/*physiology | 2 | 7.0 |
Interferon Type II/*metabolism | 2 | 3.0 |
Interleukin-12/pharmacology | 13 | 26.0 |
DNA-Binding Proteins/*physiology | 5 | 0.0 |
*HIV Long Terminal Repeat | 3 | 3.0 |
NF-kappa B/*physiology | 5 | 5.0 |
Transcription Factors/*physiology | 4 | 0.0 |
Antibodies, Monoclonal/*pharmacology | 10 | 5.0 |
Arthritis, Rheumatoid/*immunology | 14 | 6.0 |
Synovial Fluid/immunology | 4 | 10.0 |
Dexamethasone/pharmacology | 5 | 1.0 |
Isoxazoles/pharmacology | 2 | 13.0 |
Sirolimus/pharmacology | 3 | 4.0 |
Tacrolimus/pharmacology | 6 | 12.0 |
Protein Biosynthesis | 4 | 0.0 |
Calcineurin/physiology | 4 | 44.0 |
Immunity, Natural | 5 | 2.0 |
Proto-Oncogene Proteins/*physiology | 6 | 2.0 |
T-Lymphocytes, Helper-Inducer/immunology | 7 | 3.0 |
Intracellular Fluid/immunology/metabolism | 3 | 10.0 |
Polymorphism, Genetic/*immunology | 2 | 6.0 |
Antigens, CD58/pharmacology | 2 | 66.0 |
Antigens, CD80/pharmacology | 7 | 77.0 |
Antigens, Viral/immunology | 5 | 4.0 |
Epitopes, T-Lymphocyte/*immunology | 4 | 6.0 |
Genes, T-Cell Receptor beta | 3 | 25.0 |
Human T-lymphotropic virus 1/*immunology | 2 | 10.0 |
Peptide Fragments/immunology | 6 | 2.0 |
*Human T-lymphotropic virus 1 | 2 | 10.0 |
T-Lymphocytes/*enzymology/immunology | 7 | 30.0 |
rap1 GTP-Binding Proteins/*metabolism | 2 | 12.0 |
Antigens, CD95/*physiology | 3 | 3.0 |
Gene Expression Regulation, Neoplastic/drug effects | 2 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
Membrane Glycoproteins/biosynthesis/genetics | 4 | 8.0 |
Muromonab-CD3/pharmacology | 18 | 25.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis/genetics | 2 | 4.0 |
T-Lymphocytes/*cytology/immunology/metabolism | 2 | 50.0 |
*Regulatory Sequences, Nucleic Acid | 4 | 1.0 |
Protein-Tyrosine Kinase/*antagonists & inhibitors | 2 | 1.0 |
Antigens, CD40/biosynthesis | 5 | 18.0 |
Intercellular Adhesion Molecule-1/biosynthesis | 4 | 4.0 |
Lipopolysaccharides/pharmacology | 6 | 0.0 |
Tacrolimus/*pharmacology | 3 | 8.0 |
Tumor Necrosis Factor-alpha/analysis | 2 | 0.0 |
Immunoglobulin A/metabolism | 3 | 5.0 |
Antibodies, Antinuclear/biosynthesis | 3 | 60.0 |
B-Lymphocytes/physiology | 2 | 3.0 |
DNA/immunology | 2 | 4.0 |
Immunoglobulin G/metabolism | 4 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/*physiology | 2 | 18.0 |
src Homology Domains/immunology | 3 | 11.0 |
Interleukin-10/*biosynthesis | 6 | 9.0 |
Interleukin-4/*biosynthesis | 14 | 26.0 |
Lymphocyte Activation/drug effects/immunology | 4 | 6.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
T-Lymphocytes/drug effects/*immunology/*metabolism | 4 | 40.0 |
Antibodies, Monoclonal/therapeutic use | 3 | 1.0 |
Antigens, CD40 | 8 | 14.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 2 | 6.0 |
Immunoglobulin M/metabolism | 3 | 3.0 |
Dendritic Cells/*physiology | 3 | 3.0 |
Keratinocytes/*physiology | 3 | 8.0 |
Antigens, CD28/*biosynthesis/*genetics | 2 | 100.0 |
Rabbits | 6 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/genetics | 2 | 2.0 |
Antibody Specificity | 14 | 1.0 |
Lymphoma, B-Cell/immunology/therapy | 2 | 66.0 |
Tissue Distribution | 6 | 0.0 |
Antigens, CD80/*immunology/metabolism | 3 | 60.0 |
*Epitopes, T-Lymphocyte | 2 | 20.0 |
Membrane Glycoproteins/*immunology/metabolism | 3 | 18.0 |
Multiple Sclerosis/immunology | 3 | 7.0 |
Theilovirus/*immunology | 2 | 66.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 5 | 1.0 |
Receptors, Cell Surface/metabolism | 2 | 0.0 |
Antibodies, Anti-Idiotypic/*immunology | 2 | 4.0 |
Cytokines/biosynthesis/immunology | 3 | 16.0 |
HIV Infections/immunology/virology | 3 | 11.0 |
Interleukin-6/metabolism | 2 | 0.0 |
Karyotyping | 5 | 0.0 |
Multiple Myeloma/genetics/immunology/*pathology | 3 | 60.0 |
Lipopolysaccharides/*pharmacology | 4 | 0.0 |
Adjuvants, Immunologic/physiology | 7 | 15.0 |
Transforming Growth Factor beta/*physiology | 2 | 1.0 |
Tritium | 2 | 0.0 |
Immunoglobulin G/biosynthesis | 5 | 3.0 |
Cyclic AMP/physiology | 5 | 4.0 |
Forskolin/pharmacology | 8 | 2.0 |
Interleukin-10/secretion | 2 | 6.0 |
Interleukin-2/analysis | 2 | 4.0 |
Interleukin-4/secretion | 5 | 12.0 |
Lymphocyte Activation/drug effects/*physiology | 4 | 23.0 |
Lymphokines/*secretion | 2 | 4.0 |
Second Messenger Systems | 6 | 6.0 |
Antigens, CD27 | 5 | 11.0 |
Antigens, CD45 | 11 | 5.0 |
Peptide Fragments | 2 | 2.0 |
Antibodies, Monoclonal/genetics/immunology | 2 | 18.0 |
DNA, Recombinant/genetics | 2 | 3.0 |
Escherichia coli/genetics | 3 | 0.0 |
Immunoglobulin Fragments/genetics/*immunology | 3 | 42.0 |
Killer Cells, Lymphokine-Activated/immunology | 3 | 4.0 |
Transplantation, Autologous | 2 | 0.0 |
Antigens, Differentiation/genetics/*metabolism | 4 | 16.0 |
HIV Infections/immunology | 5 | 5.0 |
Serologic Tests | 2 | 2.0 |
Cytoplasm/immunology | 7 | 7.0 |
Microspheres | 2 | 1.0 |
Recombinant Fusion Proteins/immunology/pharmacology | 2 | 28.0 |
T-Lymphocytes/drug effects/*immunology/metabolism | 3 | 13.0 |
Graft vs Host Disease/*immunology | 2 | 7.0 |
Membrane Glycoproteins/immunology/*metabolism | 3 | 7.0 |
Plasmids | 3 | 0.0 |
Tumor Necrosis Factor-alpha/immunology | 3 | 2.0 |
Receptors, Interleukin-2/*analysis | 2 | 2.0 |
Calcium/*metabolism | 3 | 0.0 |
*MAP Kinase Signaling System | 3 | 2.0 |
Protein Kinases/metabolism | 3 | 0.0 |
Tyrosine/*metabolism | 7 | 2.0 |
Antigens, CD28/*immunology/metabolism | 6 | 85.0 |
Enterotoxins/immunology | 9 | 16.0 |
Interleukin-2/immunology/pharmacology | 2 | 50.0 |
Superantigens/immunology | 10 | 21.0 |
Th1 Cells/immunology | 10 | 5.0 |
Antigens, CD4/*immunology | 8 | 2.0 |
Antigens, CD95/*immunology | 2 | 5.0 |
Membrane Glycoproteins/genetics/*immunology | 2 | 3.0 |
RNA, Messenger/genetics | 21 | 0.0 |
Antigens, CD3/pharmacology | 5 | 31.0 |
Cell Survival/drug effects | 4 | 0.0 |
Sphingosine/*analogs & derivatives/pharmacology | 2 | 6.0 |
*Antigens, Differentiation | 4 | 4.0 |
Flow Cytometry/*methods | 3 | 1.0 |
T-Lymphocytes/*immunology/pathology | 5 | 9.0 |
Receptors, Interleukin-2/*physiology | 3 | 13.0 |
Amino Acid Motifs/genetics | 2 | 3.0 |
Antigens, CD28/immunology/metabolism | 12 | 92.0 |
Antigens, CD80/immunology/metabolism | 3 | 33.0 |
B-Lymphocytes/immunology/*metabolism | 3 | 5.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Point Mutation/*immunology | 2 | 40.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Interleukin-10/biosynthesis/genetics | 2 | 13.0 |
T-Lymphocytes, Helper-Inducer/cytology/*immunology | 2 | 22.0 |
Antigens, CD27/*immunology | 5 | 83.0 |
Cell Adhesion/immunology | 9 | 5.0 |
Germinal Center/immunology | 2 | 16.0 |
Isoenzymes/physiology | 3 | 6.0 |
Protein Kinase C/physiology | 10 | 6.0 |
Proto-Oncogene Proteins/physiology | 3 | 2.0 |
Leukocytes, Mononuclear/*immunology | 4 | 2.0 |
*Cell Aging | 3 | 5.0 |
Immune System | 3 | 25.0 |
T-Lymphocytes/metabolism/*pathology | 2 | 14.0 |
Chromosomes, Human, Pair 2/*genetics | 6 | 3.0 |
Genetic Markers | 4 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Antigens, CD18/*metabolism | 2 | 10.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Lymphocyte Function-Associated Antigen-1/*metabolism | 4 | 14.0 |
Aging/immunology | 6 | 10.0 |
*Frail Elderly | 2 | 22.0 |
Immunologic Memory/physiology | 3 | 25.0 |
Reference Values | 17 | 0.0 |
Antigens, CD80/*genetics/immunology | 3 | 60.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 8 | 28.0 |
Receptors, Antigen, T-Cell, alpha-beta/immunology | 8 | 12.0 |
Thymus Gland/cytology/*immunology | 3 | 9.0 |
HIV-1/*immunology/physiology | 2 | 5.0 |
Biological Markers/blood | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Follow-Up Studies | 10 | 0.0 |
Intercellular Adhesion Molecule-1/blood | 2 | 2.0 |
Interleukin-12/biosynthesis/*immunology | 2 | 50.0 |
Isoantigens/*immunology | 13 | 17.0 |
Monocytes/*immunology | 12 | 2.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Immunoglobulin Variable Region/genetics | 3 | 2.0 |
Leukocytes, Mononuclear/metabolism | 2 | 0.0 |
*Transduction, Genetic | 2 | 2.0 |
Enzyme Activation/radiation effects | 2 | 8.0 |
*JNK Mitogen-Activated Protein Kinases | 6 | 6.0 |
Mitogen-Activated Protein Kinase Kinases/*metabolism | 2 | 3.0 |
Ultraviolet Rays | 5 | 0.0 |
src-Family Kinases/*metabolism | 2 | 1.0 |
Antigens, CD2/*metabolism | 5 | 15.0 |
Chimeric Proteins/metabolism | 2 | 1.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*metabolism | 2 | 5.0 |
Phosphoproteins/*metabolism | 4 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
CD8-Positive T-Lymphocytes/*metabolism | 3 | 8.0 |
T-Lymphocyte Subsets/*metabolism | 5 | 16.0 |
Antigens, Differentiation, T-Lymphocyte/*metabolism | 9 | 7.0 |
HIV-1/drug effects/*physiology | 2 | 5.0 |
Receptors, HIV/metabolism | 2 | 6.0 |
Fetal Blood/*immunology | 6 | 7.0 |
Gestational Age | 2 | 0.0 |
Receptors, Interleukin-2/*blood | 2 | 3.0 |
Thymidine/pharmacology | 2 | 12.0 |
Xenograft Model Antitumor Assays | 2 | 0.0 |
Antigens, CD28/genetics/metabolism | 2 | 66.0 |
Apoptosis/*physiology | 8 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 4 | 0.0 |
Intracellular Fluid/immunology | 3 | 20.0 |
Lymphocyte Function-Associated Antigen-1/biosynthesis | 3 | 14.0 |
Membrane Glycoproteins/biosynthesis | 15 | 9.0 |
Th1 Cells/drug effects/*immunology | 2 | 25.0 |
Genes, Reporter/immunology | 2 | 16.0 |
Luciferases/biosynthesis/genetics | 2 | 3.0 |
T-Lymphocytes/enzymology/*immunology/*metabolism | 2 | 40.0 |
Th1 Cells/enzymology/immunology | 2 | 66.0 |
Th2 Cells/enzymology/immunology | 2 | 100.0 |
L-Selectin/analysis | 3 | 15.0 |
Mice, Nude | 3 | 0.0 |
Receptors, Antigen, T-Cell, gamma-delta/*immunology | 2 | 4.0 |
Intercellular Adhesion Molecule-1/immunology | 5 | 11.0 |
Lymphocyte Function-Associated Antigen-1/*immunology | 4 | 20.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 3 | 3.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Protein Binding/drug effects | 3 | 0.0 |
Membrane Glycoproteins/genetics/*metabolism | 3 | 1.0 |
Receptor Aggregation | 9 | 9.0 |
Lymphoid Tissue/metabolism | 2 | 7.0 |
Molecular Weight | 11 | 0.0 |
Organ Specificity | 2 | 0.0 |
Proteins/*metabolism | 7 | 0.0 |
Interferon-alpha/pharmacology | 2 | 2.0 |
Serine/*metabolism | 2 | 2.0 |
Leukapheresis | 3 | 2.0 |
T-Lymphocytes/*cytology/*metabolism | 2 | 33.0 |
Antigens, Differentiation, T-Lymphocyte/genetics/*metabolism | 3 | 37.0 |
Receptors, Antigen, T-Cell/genetics/*metabolism | 3 | 16.0 |
CA-15-3 Antigen/genetics/*immunology | 2 | 33.0 |
Leukocytes, Mononuclear/drug effects/immunology/metabolism | 2 | 14.0 |
T-Lymphocytes/drug effects/immunology/metabolism | 2 | 11.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 2 | 2.0 |
Actins/*metabolism | 2 | 0.0 |
*Ultraviolet Rays | 3 | 1.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Isoenzymes/metabolism/*physiology | 2 | 33.0 |
Antigens, CD40/metabolism | 7 | 10.0 |
Interleukin-15/*physiology | 2 | 28.0 |
Myasthenia Gravis/*immunology | 3 | 13.0 |
Telomerase/metabolism | 4 | 7.0 |
Antibodies/*immunology | 2 | 1.0 |
Antigens, CD8/immunology | 4 | 5.0 |
Anti-HIV Agents/administration & dosage/*therapeutic use | 3 | 6.0 |
Antigens, CD8/*analysis | 6 | 8.0 |
Consensus Sequence | 7 | 0.0 |
Imidazoles/pharmacology | 4 | 1.0 |
Pyridines/pharmacology | 4 | 1.0 |
Fluorescent Antibody Technique, Direct | 3 | 2.0 |
Membrane Glycoproteins/*blood | 5 | 9.0 |
Antigen Presentation/immunology | 2 | 2.0 |
Antigens, CD95/physiology | 5 | 6.0 |
Biopsy | 4 | 0.0 |
T-Lymphocytes/immunology/pathology | 2 | 3.0 |
Antigens, CD28/blood | 7 | 87.0 |
Antigens, Differentiation/blood | 2 | 18.0 |
HLA-DR Antigens/blood | 3 | 5.0 |
Lymphocytes/*immunology | 7 | 1.0 |
Membrane Glycoproteins/blood | 2 | 6.0 |
Monocytes/drug effects/immunology | 2 | 5.0 |
Diabetes Mellitus, Type 1/immunology | 2 | 11.0 |
Immune Sera/pharmacology | 3 | 3.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 6 | 3.0 |
Phosphorylation/drug effects | 6 | 0.0 |
HIV Infections/*immunology/physiopathology | 2 | 20.0 |
Cell Aging/immunology | 5 | 45.0 |
Antigens, CD/analysis/physiology | 3 | 25.0 |
Cytokines/*biosynthesis/genetics | 4 | 5.0 |
Major Histocompatibility Complex | 5 | 2.0 |
Membrane Glycoproteins/immunology/*physiology | 3 | 17.0 |
Recombinant Proteins/metabolism | 7 | 0.0 |
Tumor Necrosis Factor-alpha/*genetics | 2 | 0.0 |
Virus Integration | 2 | 3.0 |
Virus Replication/*drug effects | 2 | 1.0 |
Histocompatibility Antigens Class II/biosynthesis | 3 | 6.0 |
Reverse Transcriptase Inhibitors/*therapeutic use | 3 | 2.0 |
Viremia | 2 | 4.0 |
Antigens, CD30/metabolism | 2 | 10.0 |
HLA-DR Antigens/*metabolism | 2 | 3.0 |
Macrophage-1 Antigen/metabolism | 4 | 5.0 |
Antigens, CD2/physiology | 7 | 29.0 |
Conserved Sequence | 5 | 0.0 |
Interferon Type II/*biosynthesis/genetics | 2 | 9.0 |
Leukocytes, Mononuclear/immunology/metabolism | 3 | 7.0 |
Regulatory Sequences, Nucleic Acid/*immunology | 2 | 25.0 |
Antigens/immunology | 3 | 2.0 |
Antigens, Bacterial/*immunology | 7 | 6.0 |
Bacterial Outer Membrane Proteins/*immunology | 2 | 8.0 |
Epithelial Cells/immunology | 3 | 8.0 |
Transplantation Immunology | 3 | 4.0 |
Antigens, CD80/immunology/*metabolism | 5 | 50.0 |
Antigens, Differentiation/immunology/*metabolism | 2 | 18.0 |
Autoimmune Diseases/*immunology | 6 | 3.0 |
Antigens, CD27/immunology | 5 | 55.0 |
Graft Rejection/*immunology/prevention & control | 2 | 28.0 |
Cell Adhesion Molecules/*metabolism | 4 | 1.0 |
Phorbols/pharmacology | 2 | 33.0 |
Phosphotyrosine/metabolism | 12 | 2.0 |
T-Lymphocytes/drug effects/*enzymology/*immunology | 2 | 40.0 |
Interleukin-2/genetics/secretion | 4 | 57.0 |
Antigens, Differentiation, T-Lymphocyte/immunology | 25 | 13.0 |
Drug Administration Schedule | 2 | 0.0 |
Liver Transplantation/*immunology | 3 | 9.0 |
Methylprednisolone/therapeutic use | 2 | 4.0 |
Interleukin-5/biosynthesis/genetics | 2 | 25.0 |
Receptors, Antigen, T-Cell | 3 | 7.0 |
Simplexvirus/immunology | 2 | 9.0 |
Dimethyl Sulfoxide/pharmacology | 3 | 3.0 |
*MAP Kinase Kinase 4 | 3 | 5.0 |
Antigens, CD80/genetics/metabolism | 4 | 80.0 |
Membrane Glycoproteins/genetics/metabolism | 2 | 2.0 |
Antibodies, Blocking/pharmacology | 10 | 11.0 |
Oligopeptides/pharmacology | 3 | 1.0 |
Antibodies, Viral/biosynthesis | 2 | 5.0 |
Cytotoxicity, Immunologic/genetics | 2 | 11.0 |
Interleukin-4/physiology | 2 | 5.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
NF-kappa B/physiology | 2 | 2.0 |
Neoplasms/*therapy | 2 | 1.0 |
Neoplasms, Experimental/immunology/therapy | 2 | 40.0 |
Receptors, Nerve Growth Factor/genetics/*physiology | 2 | 50.0 |
Receptors, Tumor Necrosis Factor/genetics/*physiology | 2 | 11.0 |
Gene Expression Regulation/*drug effects | 4 | 0.0 |
Antigens, CD29/*physiology | 2 | 9.0 |
Fibronectins/*metabolism | 2 | 2.0 |
Blood Donors | 3 | 1.0 |
Antigens, CD/*blood | 4 | 2.0 |
Antigens, CD80/*blood | 5 | 55.0 |
Fetal Blood/immunology | 2 | 2.0 |
Lymphocytes/drug effects/*immunology | 2 | 4.0 |
Antibodies, Monoclonal/immunology/*pharmacology | 4 | 8.0 |
CD8-Positive T-Lymphocytes/drug effects/*immunology | 3 | 23.0 |
Superantigens/*pharmacology | 5 | 17.0 |
DNA/chemistry | 2 | 0.0 |
DNA Primers/chemistry | 5 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*genetics | 2 | 11.0 |
HMGA1a Protein | 2 | 11.0 |
Aorta | 2 | 1.0 |
Endothelium, Vascular/*immunology | 2 | 2.0 |
Umbilical Veins | 3 | 0.0 |
T-Lymphocytes/immunology/*physiology | 7 | 12.0 |
HLA Antigens/metabolism | 2 | 6.0 |
Histocompatibility Antigens Class I/metabolism | 4 | 6.0 |
Receptors, Antigen, T-Cell/biosynthesis | 3 | 21.0 |
Protein-Tyrosine Kinase/metabolism/*physiology | 2 | 7.0 |
Antigens, Differentiation/*immunology/metabolism | 2 | 40.0 |
Cell Death/genetics/immunology | 2 | 22.0 |
Immunity, Natural/genetics | 2 | 3.0 |
Killer Cells, Natural/immunology/metabolism | 2 | 6.0 |
L Cells (Cell Line) | 14 | 6.0 |
src Homology Domains/genetics/*physiology | 2 | 15.0 |
Antigens, CD/biosynthesis/genetics | 3 | 8.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/genetics | 2 | 20.0 |
Cell Division/drug effects/physiology | 3 | 1.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/*physiology | 2 | 20.0 |
Receptor Cross-Talk | 3 | 7.0 |
Antibodies, Monoclonal/*therapeutic use | 6 | 1.0 |
Leprosy, Lepromatous/metabolism/pathology/*therapy | 2 | 100.0 |
Leukocytes, Mononuclear/*immunology/pathology | 2 | 40.0 |
Alkaloids/*pharmacology | 2 | 3.0 |
*Benzylisoquinolines | 2 | 18.0 |
Isoquinolines/pharmacology | 5 | 4.0 |
*Tetrahydroisoquinolines | 2 | 3.0 |
Antigens, CD80 | 28 | 87.0 |
Membrane Glycoproteins | 2 | 4.0 |
Receptors, Antigen, T-Cell, gamma-delta | 3 | 5.0 |
Binding, Competitive | 7 | 0.0 |
Mitogens/*pharmacology | 4 | 3.0 |
NF-kappa B/genetics/metabolism | 3 | 5.0 |
Antigens, CD14/analysis | 2 | 1.0 |
Antigens, CD40/analysis/*genetics | 2 | 66.0 |
Lymphocyte Activation/genetics/immunology | 4 | 30.0 |
Multigene Family/*immunology | 2 | 8.0 |
Catalysis | 2 | 0.0 |
Interleukin-2/secretion | 10 | 13.0 |
Thymus Gland/*metabolism | 2 | 11.0 |
Caspases/metabolism | 3 | 0.0 |
Cell Aging/*physiology | 2 | 3.0 |
Antigens, CD/immunology/*metabolism | 5 | 10.0 |
B-Lymphocytes/*drug effects/immunology | 2 | 6.0 |
Monocytes/*drug effects/immunology | 3 | 7.0 |
DNA/analysis | 2 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Antigens, CD44/biosynthesis | 2 | 6.0 |
Cell Adhesion Molecules/biosynthesis | 6 | 7.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Antigens, Differentiation/biosynthesis/metabolism | 2 | 66.0 |
Lymphocyte Activation/genetics/*immunology | 5 | 27.0 |
Mast-Cell Sarcoma | 4 | 40.0 |
Transfection/immunology | 7 | 14.0 |
Immunologic Memory/*immunology | 5 | 15.0 |
Gene Expression/drug effects | 2 | 0.0 |
Protein Kinase C/antagonists & inhibitors | 6 | 4.0 |
Antigens, CD18/physiology | 2 | 16.0 |
Superantigens/*immunology | 8 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/genetics | 3 | 9.0 |
Chromosomes, Human, Pair 2 | 5 | 2.0 |
Plasmids/genetics | 2 | 0.0 |
Th1 Cells/metabolism | 2 | 7.0 |
Cytokines/biosynthesis/drug effects | 2 | 15.0 |
Peptides/pharmacology | 3 | 1.0 |
T-Lymphocytes/virology | 4 | 5.0 |
Antigens, CD28/analysis/immunology | 2 | 100.0 |
Antigens, CD3/analysis/immunology | 2 | 16.0 |
Neoplasm Metastasis | 2 | 0.0 |
HLA-D Antigens/*immunology | 2 | 3.0 |
CD8-Positive T-Lymphocytes/*immunology/metabolism | 5 | 20.0 |
*Chemokines, C | 2 | 25.0 |
Lymphokines/*genetics/*metabolism | 2 | 14.0 |
Sialoglycoproteins/*genetics/*metabolism | 2 | 66.0 |
Isoantigens | 2 | 7.0 |
*CD4 Lymphocyte Count | 2 | 0.0 |
HIV Infections/*drug therapy/*immunology | 3 | 5.0 |
HIV Protease Inhibitors/*therapeutic use | 2 | 1.0 |
Antigens, CD45/*blood | 3 | 30.0 |
Colonic Neoplasms/immunology | 2 | 9.0 |
Interferon Type II/*secretion | 2 | 10.0 |
Cell Death/immunology | 5 | 15.0 |
RNA, Viral/*blood | 2 | 1.0 |
Ritonavir/administration & dosage/*therapeutic use | 2 | 33.0 |
Saquinavir/administration & dosage/*therapeutic use | 2 | 22.0 |
Bronchoalveolar Lavage Fluid/chemistry/cytology | 2 | 5.0 |
Leukocytes, Mononuclear/cytology | 4 | 8.0 |
Intercellular Adhesion Molecule-1/*biosynthesis | 2 | 4.0 |
Intracellular Fluid/metabolism | 3 | 2.0 |
Cytokines/physiology | 2 | 1.0 |
Growth Inhibitors/pharmacology | 3 | 2.0 |
Microscopy, Fluorescence | 2 | 0.0 |
RNA, Messenger/*analysis | 3 | 0.0 |
Integrins/metabolism | 2 | 1.0 |
Herpesvirus 4, Human/*isolation & purification | 3 | 7.0 |
Kidney Transplantation | 2 | 1.0 |
Treatment Outcome | 8 | 0.0 |
Enzyme Precursors/metabolism | 2 | 1.0 |
Phosphoproteins/chemistry/*metabolism | 2 | 3.0 |
Antigens, CD19/immunology | 2 | 5.0 |
Antigens, CD20/*immunology | 2 | 16.0 |
Leukemia, B-Cell/*immunology/pathology | 2 | 40.0 |
Receptor-CD3 Complex, Antigen, T-Cell/*immunology | 3 | 23.0 |
Tumor Cells, Cultured/immunology | 4 | 4.0 |
CD4-Positive T-Lymphocytes/*drug effects | 2 | 6.0 |
CD8-Positive T-Lymphocytes/*cytology/immunology | 3 | 27.0 |
Interleukin-2/immunology/metabolism | 2 | 33.0 |
T-Lymphocyte Subsets/*cytology/immunology | 2 | 22.0 |
Cytokines/*immunology | 3 | 3.0 |
Interleukin-2/antagonists & inhibitors/biosynthesis | 3 | 27.0 |
Antigens, CD28/immunology/*physiology | 6 | 85.0 |
Interleukin-6/physiology | 2 | 3.0 |
Cytokines/*biosynthesis/immunology | 2 | 15.0 |
Phytohemagglutinins | 4 | 4.0 |
Cytomegalovirus Infections/complications/*immunology | 2 | 66.0 |
Antigens, CD28/*immunology/pharmacology | 3 | 100.0 |
Immunotherapy/*methods | 7 | 5.0 |
Integrins/biosynthesis | 2 | 8.0 |
Intestinal Mucosa/*immunology/pathology | 2 | 7.0 |
Leukocytes, Mononuclear | 2 | 4.0 |
Binding Sites/genetics | 4 | 0.0 |
*Mitogen-Activated Protein Kinases | 14 | 4.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Protein Kinases/*metabolism | 3 | 0.0 |
Protein-Tyrosine Kinase/*metabolism/physiology | 2 | 20.0 |
T-Lymphocytes/enzymology | 3 | 7.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 6 | 1.0 |
Antigens, CD28/immunology/physiology | 2 | 100.0 |
HIV-1/genetics/*immunology | 2 | 2.0 |
T-Lymphocytes/*immunology/virology | 4 | 22.0 |
Binding Sites, Antibody | 5 | 1.0 |
Interleukin-4/*genetics | 3 | 6.0 |
Lymphocytes, Tumor-Infiltrating/immunology | 4 | 10.0 |
Lymphocyte Function-Associated Antigen-1/metabolism | 3 | 6.0 |
Receptors, Tumor Necrosis Factor/metabolism | 3 | 1.0 |
Injections, Subcutaneous | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis | 7 | 3.0 |
HIV-1/*physiology | 9 | 1.0 |
*Variation (Genetics) | 2 | 0.0 |
CD4-Positive T-Lymphocytes | 2 | 0.0 |
Interferon Type II/immunology | 3 | 3.0 |
Chagas Disease/*immunology | 2 | 11.0 |
Interferon Type II/analysis | 2 | 2.0 |
Interleukin-4/analysis | 2 | 5.0 |
Antigens, CD8/metabolism | 4 | 7.0 |
CD4-Positive T-Lymphocytes/immunology/virology | 4 | 14.0 |
CD8-Positive T-Lymphocytes/immunology/virology | 2 | 40.0 |
Interphase | 2 | 1.0 |
CD4-Positive T-Lymphocytes/drug effects | 2 | 3.0 |
Receptors, Interleukin-2/genetics | 4 | 10.0 |
Adenoviridae/genetics | 2 | 0.0 |
HLA Antigens/genetics/immunology | 2 | 6.0 |
Peptides/immunology | 4 | 2.0 |
Immunoglobulin Fragments/*immunology | 2 | 14.0 |
Interleukin-2/genetics/*secretion | 2 | 100.0 |
Nuclear Proteins/metabolism | 6 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Cell Aging/*immunology | 4 | 80.0 |
Transcription Factors/biosynthesis | 4 | 4.0 |
T-Lymphocytes/cytology/drug effects/*metabolism | 2 | 28.0 |
Dinoprostone/pharmacology | 3 | 3.0 |
Interferon Type II/genetics | 2 | 2.0 |
Alternative Splicing/*genetics | 2 | 1.0 |
Cytosol/metabolism | 2 | 0.0 |
Membrane Proteins/genetics | 4 | 1.0 |
Antigens, CD28/*biosynthesis/immunology | 2 | 100.0 |
Interleukins/secretion | 2 | 25.0 |
Membrane Proteins/physiology | 3 | 3.0 |
*Mitogen-Activated Protein Kinase Kinases | 9 | 9.0 |
Mitogen-Activated Protein Kinases/physiology | 3 | 2.0 |
Protein Kinases/physiology | 3 | 6.0 |
Receptors, IgG/physiology | 2 | 5.0 |
DNA Fingerprinting | 2 | 1.0 |
Synovial Fluid/cytology/immunology | 2 | 10.0 |
Concanavalin A/pharmacology | 6 | 2.0 |
Drug Interactions | 3 | 0.0 |
Proto-Oncogene Proteins c-rel | 12 | 21.0 |
Cyclin-Dependent Kinases/metabolism | 2 | 0.0 |
Immunosuppressive Agents/*metabolism | 3 | 25.0 |
*Proto-Oncogene Proteins | 4 | 0.0 |
RNA, Messenger/isolation & purification | 2 | 2.0 |
Alternative Splicing | 3 | 0.0 |
*Antibody Formation | 2 | 2.0 |
Cytokines/*blood | 4 | 1.0 |
Lymphocyte Subsets | 2 | 1.0 |
Culture Media | 3 | 0.0 |
HIV Envelope Protein gp120/*immunology | 2 | 1.0 |
HLA-B7 Antigen/*immunology | 3 | 75.0 |
Phosphatidylinositol Diacylglycerol-Lyase | 2 | 2.0 |
Antigens, CD27/biosynthesis | 2 | 33.0 |
Neoplasms, Experimental/immunology/*therapy | 2 | 22.0 |
Antibodies, Bispecific/immunology/*therapeutic use | 3 | 75.0 |
HLA-A2 Antigen/immunology | 3 | 8.0 |
Antigens, CD27/genetics/*immunology | 2 | 100.0 |
Spleen/cytology | 5 | 2.0 |
Antigens, CD/genetics/*immunology | 4 | 11.0 |
Cell Lineage/immunology | 2 | 6.0 |
Immunoglobulin G/blood | 2 | 0.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Antigens, CD45/*immunology | 2 | 6.0 |
Zidovudine/therapeutic use | 4 | 2.0 |
Cytotoxicity, Immunologic/*immunology | 3 | 6.0 |
Fetal Blood/cytology/*immunology | 2 | 10.0 |
Epitope Mapping | 2 | 0.0 |
*Lymphocyte Activation/drug effects | 17 | 16.0 |
Signal Transduction/drug effects/*immunology | 2 | 5.0 |
Major Histocompatibility Complex/*immunology | 4 | 10.0 |
Tumor Necrosis Factor-alpha/*immunology | 2 | 1.0 |
Antigens, Differentiation/genetics/*immunology | 2 | 15.0 |
Antigens, CD11/analysis | 3 | 10.0 |
Bronchoalveolar Lavage Fluid/immunology | 2 | 5.0 |
Cell Adhesion Molecules/analysis | 3 | 1.0 |
Macrophages, Alveolar/immunology | 2 | 12.0 |
T-Lymphocytes/drug effects/*metabolism | 2 | 4.0 |
Cyclic AMP/*physiology | 3 | 3.0 |
Antigens, CD | 7 | 5.0 |
Leukemia, Lymphocytic, Chronic/*immunology | 2 | 13.0 |
Receptors, Interleukin-2/physiology | 4 | 8.0 |
*Cell Adhesion | 3 | 1.0 |
HIV-1/isolation & purification | 2 | 4.0 |
Peptide Mapping | 2 | 0.0 |
Phosphatidylinositols/metabolism | 3 | 2.0 |
Phosphoserine/metabolism | 2 | 2.0 |
Interleukin-15/pharmacology | 2 | 8.0 |
Interleukins/*pharmacology | 4 | 5.0 |
Antibodies, Bispecific/*immunology | 6 | 31.0 |
Bone Marrow/*immunology/pathology | 2 | 11.0 |
Leukemia, B-Cell, Acute/*immunology/pathology | 2 | 66.0 |
Anti-Bacterial Agents/*pharmacology | 3 | 2.0 |
Antigens, CD/genetics/*metabolism | 4 | 4.0 |
Receptors, Lymphocyte Homing | 2 | 5.0 |
T-Lymphocytes/*immunology/*virology | 3 | 30.0 |
Apoptosis/drug effects/*immunology | 2 | 5.0 |
Binding Sites/immunology | 3 | 5.0 |
CD4-Positive T-Lymphocytes/drug effects/*immunology/physiology | 2 | 100.0 |
Cycloheximide/pharmacology | 5 | 0.0 |
Protein-Tyrosine-Phosphatase/metabolism | 2 | 1.0 |
T-Lymphocytes/*enzymology/*immunology | 5 | 50.0 |
HLA-A2 Antigen/metabolism | 3 | 18.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/immunology | 2 | 66.0 |
Protein-Tyrosine Kinase/immunology | 2 | 16.0 |
HIV Seronegativity/immunology | 3 | 5.0 |
Herpesvirus 4, Human/immunology | 3 | 4.0 |
Orthomyxoviridae/immunology | 2 | 10.0 |
Antigens, CD/*biosynthesis/immunology | 2 | 8.0 |
Liver Cirrhosis, Biliary/*immunology | 2 | 5.0 |
Enterotoxins/pharmacology | 4 | 6.0 |
Macrophage Activation | 2 | 1.0 |
Staphylococcus aureus/immunology | 8 | 7.0 |
Superantigens/pharmacology | 3 | 12.0 |
T-Lymphocytes/enzymology/*immunology/metabolism | 5 | 71.0 |
Reactive Oxygen Species/*metabolism | 3 | 1.0 |
T-Lymphocytes/cytology/*immunology/*metabolism | 2 | 16.0 |
Binding, Competitive/immunology | 7 | 7.0 |
Receptors, Antigen, T-Cell, alpha-beta/genetics/immunology | 2 | 14.0 |
T-Lymphocytes, Cytotoxic/*immunology/metabolism | 3 | 8.0 |
Antigens, Surface/biosynthesis | 4 | 6.0 |
Interleukin-7/pharmacology | 5 | 11.0 |
*Immunosuppressive Agents | 2 | 15.0 |
Histocompatibility Antigens Class II/immunology | 6 | 3.0 |
Antigens, Differentiation/immunology/metabolism | 2 | 22.0 |
Gene Library | 3 | 0.0 |
Antigens, Bacterial/immunology | 2 | 1.0 |
*Lymphocyte Cooperation | 3 | 11.0 |
Transcription Factor AP-1/*physiology | 2 | 5.0 |
Receptors, Antigen, T-Cell/blood | 2 | 66.0 |
Interleukin-2/genetics/*immunology | 2 | 40.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology | 4 | 6.0 |
Antigen-Antibody Reactions | 3 | 0.0 |
Cell Movement/*immunology | 2 | 2.0 |
Th2 Cells/*metabolism | 2 | 8.0 |
*Lymphocyte Culture Test, Mixed | 2 | 3.0 |
CD4-Positive T-Lymphocytes/immunology/*virology | 2 | 8.0 |
Virus Replication/*immunology | 2 | 6.0 |
Inflammation/immunology | 3 | 2.0 |
Receptors, Tumor Necrosis Factor/immunology/metabolism | 2 | 50.0 |
T-Lymphocytes, Suppressor-Effector/immunology | 7 | 4.0 |
Lymphocytes/*physiology | 3 | 3.0 |
Receptors, Tumor Necrosis Factor/genetics/*immunology | 2 | 28.0 |
Intercellular Adhesion Molecule-1/analysis | 3 | 2.0 |
Skin Neoplasms/metabolism/*pathology | 2 | 5.0 |
Antigens, CD14/metabolism | 2 | 1.0 |
Antigens, CD2/pharmacology | 2 | 66.0 |
Immunohistochemistry/methods | 2 | 0.0 |
Pollen/*immunology | 3 | 17.0 |
Tyrosine/physiology | 2 | 14.0 |
Th2 Cells/immunology/*metabolism | 2 | 16.0 |
Antigens, Differentiation/chemistry/genetics/*metabolism | 2 | 33.0 |
Substrate Specificity | 6 | 0.0 |
CD4-Positive T-Lymphocytes/cytology/*drug effects/metabolism | 2 | 66.0 |
Interleukin-7/*pharmacology | 4 | 9.0 |
Thymus Gland/cytology | 3 | 3.0 |
*Disease Models, Animal | 3 | 0.0 |
Virus Replication/immunology | 3 | 5.0 |
HIV-1/*pathogenicity/physiology | 2 | 6.0 |
Immunologic Memory/immunology | 2 | 5.0 |
Cell Adhesion Molecules/*immunology | 3 | 5.0 |
Antigens, CD45/physiology | 2 | 13.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck)/physiology | 2 | 14.0 |
HIV Infections/*immunology/virology | 3 | 4.0 |
Multivariate Analysis | 3 | 0.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
Receptors, Tumor Necrosis Factor/physiology | 2 | 2.0 |
Neoplasms/immunology | 2 | 3.0 |
Antigens, CD57/*analysis | 2 | 22.0 |
B-Lymphocytes/metabolism | 3 | 1.0 |
Monocytes/*metabolism | 3 | 0.0 |
Fibronectins/physiology | 2 | 5.0 |
Point Mutation | 3 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 4 | 0.0 |
Tyrosine | 4 | 3.0 |
Enterotoxins/*immunology | 12 | 16.0 |
Tetradecanoylphorbol Acetate/immunology | 2 | 33.0 |
Antigens, Differentiation, Myelomonocytic/genetics | 2 | 11.0 |
Apoptosis/drug effects/immunology | 2 | 11.0 |
Carcinogens/pharmacology | 2 | 2.0 |
T-Lymphocytes/cytology/*immunology/metabolism | 4 | 19.0 |
Bone Marrow Transplantation/*immunology | 3 | 2.0 |
Nuclear Family | 2 | 0.0 |
Histocompatibility Antigens Class II/physiology | 2 | 10.0 |
Peptides/immunology/therapeutic use | 2 | 66.0 |
Antigens, CD28/biosynthesis/*physiology | 5 | 100.0 |
Skin/immunology/pathology | 2 | 4.0 |
DNA Fragmentation | 3 | 0.0 |
Dust | 2 | 6.0 |
Mites/*immunology | 2 | 4.0 |
Arthritis, Rheumatoid/immunology | 3 | 3.0 |
Th2 Cells/cytology/*immunology | 2 | 16.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 7 | 2.0 |
Cytokines/*genetics | 3 | 2.0 |
CD4-Positive T-Lymphocytes/*cytology/immunology | 2 | 8.0 |
Antigens, CD28/genetics/*immunology | 6 | 85.0 |
Down-Regulation/drug effects/*immunology | 2 | 20.0 |
Antibodies, Anti-Idiotypic/immunology | 2 | 5.0 |
Recombinant Fusion Proteins/genetics/immunology | 3 | 6.0 |
Nerve Tissue Proteins/physiology | 2 | 4.0 |
Transcription Factor AP-1/physiology | 2 | 4.0 |
Cytokines/*pharmacology | 3 | 0.0 |
Isoantigens/administration & dosage | 3 | 60.0 |
Bacterial Proteins/*metabolism | 2 | 4.0 |
Antigens, CD28/drug effects/*immunology | 2 | 66.0 |
Proto-Oncogene Proteins c-jun/immunology | 2 | 100.0 |
Cytokines/*biosynthesis/drug effects | 2 | 40.0 |
Signal Transduction/drug effects/immunology | 5 | 10.0 |
T-Lymphocytes/*drug effects/metabolism | 4 | 11.0 |
Integrin alpha4beta1 | 2 | 2.0 |
Integrins/blood | 2 | 40.0 |
Cell Adhesion/*physiology | 2 | 1.0 |
Chimeric Proteins/biosynthesis | 3 | 6.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Antigens, Differentiation/*analysis | 6 | 3.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Immunoglobulins, Fc/metabolism | 2 | 14.0 |
Cell Compartmentation | 3 | 0.0 |
Intestinal Mucosa/cytology/*immunology | 2 | 13.0 |
Cytotoxicity, Immunologic/drug effects | 6 | 4.0 |
Indoles/pharmacology | 4 | 1.0 |
Interleukin-2/genetics/immunology | 2 | 28.0 |
Maleimides/pharmacology | 4 | 4.0 |
Calcineurin/*physiology | 2 | 40.0 |
Protein Kinase C/*physiology | 2 | 2.0 |
rac GTP-Binding Proteins | 2 | 1.0 |
Antigens, Differentiation, T-Lymphocyte/*biosynthesis | 3 | 8.0 |
Receptors, Antigen, T-Cell/metabolism/*physiology | 4 | 44.0 |
Multiple Myeloma/*immunology | 3 | 8.0 |
Plasma Cells/*immunology | 3 | 10.0 |
Stimulation, Chemical | 4 | 0.0 |
T-Lymphocytes/*immunology/*metabolism | 5 | 15.0 |
Antigens, CD/immunology/*physiology | 4 | 12.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Inflammation/*immunology | 2 | 3.0 |
Blood Cells/immunology | 3 | 9.0 |
Interleukin-2/biosynthesis/*genetics | 4 | 22.0 |
*Herpesvirus 4, Human | 3 | 8.0 |
Proteins/metabolism | 5 | 0.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
T-Lymphocytes | 6 | 2.0 |
Lymphocyte Subsets/*immunology | 3 | 2.0 |
Autoantibodies/*immunology | 2 | 0.0 |
Enterotoxins/*pharmacology | 2 | 3.0 |
Antigens, CD28/analysis/*biosynthesis | 2 | 100.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Hodgkin Disease/*immunology/pathology | 2 | 12.0 |
Reed-Sternberg Cells/*immunology | 2 | 28.0 |
T-Lymphocytes/*metabolism/pathology | 3 | 23.0 |
ras Proteins/*metabolism | 2 | 1.0 |
Cytokines/*secretion | 3 | 5.0 |
Endothelium, Vascular/*physiology | 4 | 2.0 |
Antibodies, Bispecific/*pharmacology | 2 | 50.0 |
Gamma Rays | 2 | 0.0 |
Antibodies, Monoclonal/diagnostic use | 11 | 1.0 |
Recombinant Proteins | 6 | 0.0 |
Protein-Tyrosine Kinase/*immunology | 2 | 13.0 |
Interleukin-4/*pharmacology | 3 | 1.0 |
Antigens, CD/*pharmacology | 2 | 18.0 |
Autoantigens/*immunology | 3 | 1.0 |
Immunoglobulins, Fc/pharmacology | 2 | 33.0 |
Membrane Glycoproteins/*pharmacology | 2 | 2.0 |
Recombinant Fusion Proteins/pharmacology | 5 | 5.0 |
T-Lymphocyte Subsets/*immunology/secretion | 3 | 25.0 |
Antigens, CD57/*immunology | 3 | 50.0 |
Antigens, CD8/*immunology | 5 | 9.0 |
T-Lymphocyte Subsets/*physiology | 3 | 10.0 |
Receptors, Nerve Growth Factor/*physiology | 2 | 14.0 |
Receptors, Tumor Necrosis Factor/*physiology | 2 | 2.0 |
Antigens, CD28/biosynthesis/metabolism/*physiology | 2 | 100.0 |
Adjuvants, Immunologic/pharmacology | 5 | 5.0 |
Immunization, Secondary | 2 | 5.0 |
CD4-Positive T-Lymphocytes/cytology/*immunology/metabolism | 2 | 33.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Interleukin-2/*metabolism | 3 | 6.0 |
Interleukin-1/pharmacology | 7 | 1.0 |
Hodgkin Disease/*immunology | 3 | 11.0 |
Skin Diseases/*immunology | 2 | 9.0 |
Thymus Gland/immunology | 5 | 7.0 |
*Immunity, Cellular | 3 | 2.0 |
Histocompatibility Antigens Class II/*immunology | 4 | 2.0 |
Interleukin-12/immunology | 3 | 13.0 |
Gene Expression Regulation/drug effects/*immunology | 2 | 6.0 |
T-Lymphocytes, Cytotoxic/metabolism | 2 | 9.0 |
Flavonoids/pharmacology | 2 | 0.0 |
Protein-Serine-Threonine Kinases/*physiology | 2 | 1.0 |
Protein-Tyrosine Kinase/*physiology | 3 | 2.0 |
Myelin Basic Proteins/*immunology | 2 | 1.0 |
Heart Transplantation/immunology | 2 | 11.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
HIV Infections/immunology/*virology | 2 | 5.0 |
Antigen Presentation/*physiology | 2 | 18.0 |
Antigens, CD80/*biosynthesis/genetics | 3 | 33.0 |
Membrane Glycoproteins/*biosynthesis/genetics | 4 | 6.0 |
Antigen Presentation/*immunology | 3 | 3.0 |
*Gene Expression Regulation, Leukemic | 2 | 2.0 |
Common Variable Immunodeficiency/*immunology | 4 | 26.0 |
Mycobacterium leprae/*immunology | 3 | 10.0 |
Biotinylation | 2 | 1.0 |
Interleukin-10/physiology | 2 | 8.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Protein Structure, Secondary | 3 | 0.0 |
HIV Infections/drug therapy/*immunology/*virology | 2 | 25.0 |
*Viral Load | 2 | 1.0 |
Integrins/immunology | 4 | 19.0 |
Chromatography, Affinity | 3 | 0.0 |
DNA | 4 | 0.0 |
Chimeric Proteins/biosynthesis/metabolism | 3 | 15.0 |
Proto-Oncogene Proteins/biosynthesis/*metabolism | 2 | 9.0 |
HIV/*immunology | 2 | 1.0 |
Antigens, Differentiation/chemistry/*metabolism | 2 | 22.0 |
Nerve Tissue Proteins/*metabolism | 2 | 0.0 |
Immunoglobulin Variable Region/*immunology | 2 | 10.0 |
Antigen-Presenting Cells | 2 | 10.0 |
Herpesviridae Infections/*immunology | 2 | 20.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cytokines/*physiology | 3 | 1.0 |
Macrophages/*immunology | 2 | 0.0 |
Leukemia, T-Cell, Acute/pathology | 4 | 11.0 |
Neoplasm Proteins/physiology | 2 | 3.0 |
T-Lymphocyte Subsets/immunology/virology | 2 | 22.0 |
Acquired Immunodeficiency Syndrome/immunology | 2 | 2.0 |
Monocytes/*drug effects/metabolism | 2 | 2.0 |
Interleukin-2/*biosynthesis/genetics/secretion | 2 | 100.0 |
Virus Replication/*physiology | 2 | 3.0 |
Antigens, CD3/immunology/metabolism | 6 | 33.0 |
HIV Core Protein p24/immunology | 2 | 5.0 |
Antigens, CD28/genetics/*metabolism/physiology | 2 | 100.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Protein Kinase C/antagonists & inhibitors/*physiology | 3 | 10.0 |
Heterozygote Detection | 2 | 0.0 |
Synovial Membrane/*immunology | 3 | 8.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 2 | 3.0 |
*Cell Adhesion Molecules | 3 | 1.0 |
*Lectins | 2 | 1.0 |
Membrane Proteins/immunology | 3 | 5.0 |
HLA Antigens/analysis | 3 | 1.0 |
Immunity, Cellular/immunology | 4 | 6.0 |
*Transcription Factors | 4 | 0.0 |
Graft Survival | 2 | 0.0 |
Rats, Inbred BN | 3 | 6.0 |
Antigens, CD28/*genetics/metabolism | 2 | 100.0 |
DNA-Binding Proteins/*genetics/metabolism | 2 | 0.0 |
Interleukin-2/*genetics/metabolism | 4 | 40.0 |
T-Lymphocyte Subsets/immunology/*metabolism | 3 | 8.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*metabolism | 2 | 15.0 |
In Situ Hybridization | 4 | 0.0 |
Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 14 | 6.0 |
Proto-Oncogene Proteins/genetics | 3 | 0.0 |
Antigens, CD28/*metabolism/physiology | 2 | 100.0 |
Syndrome | 3 | 0.0 |
Antigens, CD80/*biosynthesis | 4 | 10.0 |
Receptors, Antigen, T-Cell, alpha-beta/metabolism | 3 | 10.0 |
Immunoconjugates/administration & dosage | 2 | 50.0 |
RNA/biosynthesis | 3 | 3.0 |
Bucladesine/pharmacology | 4 | 2.0 |
Spleen/immunology | 2 | 1.0 |
Leukocytes, Mononuclear/drug effects/immunology | 2 | 4.0 |
*Bacterial Toxins | 2 | 1.0 |
Autoimmunity/*immunology | 3 | 6.0 |
Antigens, CD/analysis/*biosynthesis | 2 | 7.0 |
Lupus Erythematosus, Systemic/immunology | 2 | 1.0 |
Family | 2 | 0.0 |
HLA-DR Antigens/immunology | 8 | 3.0 |
Cell Cycle/physiology | 2 | 0.0 |
Tuberculin/immunology | 2 | 3.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Cell Adhesion Molecules/biosynthesis/*physiology | 2 | 22.0 |
Cell Aggregation/drug effects/immunology | 2 | 33.0 |
Immunosuppression | 3 | 1.0 |
Major Histocompatibility Complex/immunology | 3 | 6.0 |
Antibodies, Bispecific | 2 | 25.0 |
Herpesvirus 4, Human | 4 | 2.0 |
Immunologic Deficiency Syndromes/*immunology | 2 | 5.0 |
Receptors, Antigen, T-Cell, gamma-delta/genetics | 2 | 8.0 |
Survival Analysis | 2 | 0.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
T-Lymphocyte Subsets/cytology/*immunology | 2 | 8.0 |
Telomere/*ultrastructure | 2 | 25.0 |
Up-Regulation/drug effects/*immunology | 2 | 13.0 |
CD4-Positive T-Lymphocytes/*virology | 2 | 2.0 |
RNA, Viral/genetics | 2 | 2.0 |
Receptors, Interleukin-2/*immunology | 3 | 7.0 |
Receptors, Antigen, T-Cell/immunology/metabolism | 3 | 27.0 |
Mice, Inbred MRL lpr | 2 | 7.0 |
Spleen/cytology/metabolism | 2 | 11.0 |
Culture Media, Serum-Free | 2 | 0.0 |
Mitogens/immunology | 3 | 11.0 |
Cell Aggregation/immunology | 2 | 10.0 |
Interleukin-10/biosynthesis | 6 | 5.0 |
Receptors, Interleukin-7 | 2 | 11.0 |
Bone Marrow Cells | 5 | 1.0 |
Antigens, Surface/physiology | 5 | 12.0 |
Fixatives | 2 | 2.0 |
T-Lymphocyte Subsets/immunology/metabolism | 4 | 8.0 |
Membrane Glycoproteins/genetics | 2 | 1.0 |
*Repressor Proteins | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 7 | 9.0 |
Fetal Blood/cytology | 6 | 3.0 |
Interleukin-10/immunology | 2 | 7.0 |
1-Phosphatidylinositol 3-Kinase | 19 | 12.0 |
Antigens, CD28/drug effects/physiology | 2 | 100.0 |
Antigens, Differentiation/*pharmacology | 3 | 50.0 |
Ovalbumin/immunology | 2 | 4.0 |
Transplantation, Heterologous | 5 | 0.0 |
Cell Adhesion Molecules/*biosynthesis | 3 | 3.0 |
Monocytes/immunology/*metabolism | 2 | 4.0 |
Interleukin-4/immunology | 2 | 3.0 |
Antigens, CD28/immunology/pharmacology | 2 | 100.0 |
Calcium/immunology | 2 | 20.0 |
Cytoplasm/*metabolism | 2 | 1.0 |
Lymphoma, T-Cell | 2 | 10.0 |
*Protein Conformation | 2 | 0.0 |
CD4-Positive T-Lymphocytes/enzymology/immunology/metabolism | 2 | 50.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Endocytosis | 3 | 0.0 |
Antigens, CD28/*metabolism/pharmacology | 2 | 100.0 |
Antigens, CD95/metabolism | 3 | 2.0 |
Interleukin-2/*immunology | 4 | 6.0 |
Antibodies, Monoclonal/*metabolism | 2 | 5.0 |
Antigens, CD4/*analysis | 3 | 1.0 |
Antigens, CD45/*analysis | 2 | 4.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 3 | 0.0 |
Cell Size | 2 | 0.0 |
*Peptide Library | 2 | 3.0 |
Phorbol Esters/pharmacology | 3 | 2.0 |
Pyrrolidines/pharmacology | 2 | 4.0 |
Thiocarbamates/pharmacology | 2 | 3.0 |
Phosphotransferases (Alcohol Group Acceptor)/*metabolism | 9 | 10.0 |
Sphingomyelin Phosphodiesterase/*metabolism | 2 | 11.0 |
Antigens, Surface/genetics/*immunology | 2 | 18.0 |
Cross-Linking Reagents/pharmacology | 2 | 1.0 |
Mitogens | 3 | 4.0 |
Autoimmunity/*physiology | 2 | 15.0 |
Human T-lymphotropic virus 1/*physiology | 2 | 7.0 |
Interleukin-5/secretion | 3 | 37.0 |
Host-Parasite Relations/immunology | 2 | 22.0 |
Leukemia, Prolymphocytic/*pathology | 2 | 40.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
3T3 Cells | 4 | 0.0 |
Adjuvants, Immunologic/therapeutic use | 2 | 4.0 |
Drug Combinations | 2 | 0.0 |
Phosphotransferases (Alcohol Group Acceptor)/metabolism | 5 | 7.0 |
Lymphocyte Activation/*radiation effects | 2 | 66.0 |
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors/*physiology | 2 | 50.0 |
Lymphoma, T-Cell/pathology | 2 | 13.0 |
Cattle/*immunology | 2 | 11.0 |
Receptors, Antigen, T-Cell, gamma-delta/*analysis | 3 | 7.0 |
Antigens, CD3/blood | 3 | 9.0 |
Leukemia, T-Cell | 4 | 11.0 |
HTLV-I Infections/*immunology | 3 | 18.0 |
HTLV-II Infections/*immunology | 2 | 33.0 |
Antigens, Differentiation, T-Lymphocyte/immunology/*physiology | 5 | 23.0 |
T-Lymphocytes/cytology/*physiology | 3 | 18.0 |
Antigens, CD28/genetics/immunology/*metabolism | 2 | 100.0 |
Interleukin-2/biosynthesis/immunology | 2 | 22.0 |
T-Lymphocyte Subsets/drug effects/*immunology | 2 | 7.0 |
Receptors, Antigen, T-Cell/*biosynthesis/genetics | 2 | 33.0 |
Epitopes/*immunology | 2 | 0.0 |
Isoantigens/pharmacology | 2 | 66.0 |
Calcium/physiology | 6 | 2.0 |
Antigens, CD/*metabolism/physiology | 2 | 25.0 |
Chemokines/metabolism | 2 | 2.0 |
Interferon Type II/biosynthesis/pharmacology | 2 | 33.0 |
Th1 Cells/cytology | 2 | 28.0 |
Interleukin-2/administration & dosage | 2 | 10.0 |
Immunomagnetic Separation | 2 | 1.0 |
Antigens, Neoplasm | 2 | 5.0 |
Receptors, Lymphocyte Homing/metabolism | 2 | 5.0 |
Skin/*immunology | 3 | 2.0 |
Tonsil/immunology | 3 | 4.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/genetics | 2 | 7.0 |
Feedback | 2 | 1.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
Immunoglobulin A/analysis | 2 | 1.0 |
Cell Aggregation | 3 | 2.0 |
Intercellular Adhesion Molecule-1/physiology | 3 | 12.0 |
CD8-Positive T-Lymphocytes/*cytology | 3 | 15.0 |
T-Lymphocyte Subsets/*cytology | 3 | 11.0 |
Cell Adhesion Molecules | 2 | 3.0 |
*Antigens, CD28 | 2 | 66.0 |
*Transplantation Immunology | 3 | 6.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Proto-Oncogene Proteins/*biosynthesis | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2 | 3 | 1.0 |
Antigens, CD27/*analysis | 2 | 20.0 |
Interleukin-1/metabolism | 2 | 0.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Antigens, CD80/genetics | 2 | 20.0 |
Phosphates/metabolism | 2 | 2.0 |
Antigens, CD80/chemistry/*genetics | 2 | 100.0 |
Microscopy, Electron | 3 | 0.0 |
Receptors, Antigen, T-Cell/genetics | 2 | 2.0 |
*Tumor Cells, Cultured | 3 | 4.0 |
Fibronectins/metabolism | 2 | 1.0 |
Antigens, CD4/*physiology | 3 | 2.0 |
Cyclooxygenase Inhibitors/pharmacology | 2 | 2.0 |
Immune Tolerance/drug effects | 2 | 7.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Cloning, Molecular/*methods | 2 | 3.0 |
Gene Products, tax/physiology | 2 | 50.0 |
Polyenes/pharmacology | 3 | 11.0 |
Sirolimus | 5 | 11.0 |
Ovarian Neoplasms/*immunology/pathology | 2 | 25.0 |
Proto-Oncogene Proteins c-raf | 4 | 3.0 |
Inositol 1,4,5-Trisphosphate/biosynthesis | 2 | 9.0 |
Inositol Phosphates/biosynthesis | 2 | 8.0 |
Cell Cycle/drug effects | 2 | 0.0 |
Interleukin-6/biosynthesis | 3 | 1.0 |
Lymphocyte Activation/drug effects/physiology | 2 | 13.0 |
Antibodies, Monoclonal/administration & dosage | 2 | 6.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Receptors, Antigen, T-Cell, alpha-beta/physiology | 2 | 28.0 |
Antigens, CD28/analysis/*immunology | 2 | 100.0 |
Crohn Disease/*immunology | 2 | 5.0 |
Enzyme-Linked Immunosorbent Assay/methods | 3 | 1.0 |
Transfection/methods | 2 | 1.0 |
Tumor Necrosis Factor-alpha/secretion | 2 | 1.0 |
Blotting, Southern | 5 | 0.0 |
*Gene Expression | 3 | 0.0 |
Immunoglobulin E/*biosynthesis | 3 | 6.0 |
Interleukin-2/biosynthesis/physiology | 2 | 28.0 |
Lung/immunology | 2 | 6.0 |
Integrins/physiology | 3 | 4.0 |
Antibodies, Monoclonal/immunology/*therapeutic use | 2 | 6.0 |
Hemagglutinins, Viral/immunology | 2 | 20.0 |
Immune System/*physiology | 4 | 6.0 |
Antigens, CD28/analysis/*physiology | 2 | 100.0 |
Antigens, CD5 | 9 | 3.0 |
Antigens, CD/immunology/physiology | 3 | 18.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
Lectins/pharmacology | 2 | 5.0 |
Antigens, CD58 | 8 | 5.0 |
Antigens, Surface/*analysis | 3 | 1.0 |
Fatal Outcome | 2 | 0.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/metabolism | 2 | 3.0 |
Interleukin-3/genetics | 2 | 22.0 |
Antigen-Presenting Cells/*physiology | 4 | 11.0 |
Integrins/*immunology | 2 | 12.0 |
Antigens, CD80/*analysis/genetics/metabolism | 2 | 100.0 |
Cell Adhesion Molecules/*physiology | 9 | 8.0 |
Antibody Formation/*physiology | 2 | 18.0 |
Lymphocyte Cooperation/immunology | 3 | 37.0 |
*Flow Cytometry | 2 | 1.0 |
Protein-Tyrosine-Phosphatase/physiology | 2 | 8.0 |
Lymphocyte Subsets/immunology | 4 | 2.0 |
L-Selectin | 3 | 4.0 |
Immunosuppression/methods | 4 | 12.0 |
Antigens, CD3/*analysis | 2 | 6.0 |
Antigens, CD/immunology/metabolism | 2 | 3.0 |
Receptors, Virus/*physiology | 2 | 5.0 |
*Chromosomes, Human, Pair 3 | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
Antigens, Surface/*metabolism | 3 | 5.0 |
Antigens, CD3/analysis/physiology | 2 | 50.0 |
Antigens, CD4/physiology | 3 | 3.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 4 | 1.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 2 | 2.0 |
Son of Sevenless Proteins | 2 | 3.0 |
Dexamethasone/*pharmacology | 3 | 1.0 |
CD4-Positive T-Lymphocytes/physiology | 5 | 9.0 |
Receptors, Interleukin-2/*biosynthesis/genetics | 2 | 33.0 |
Transcription, Genetic/*genetics | 2 | 1.0 |
Antigens, CD/analysis/*physiology | 2 | 7.0 |
Antigens, CD7 | 4 | 3.0 |
Antigens, Surface/*genetics | 3 | 4.0 |
Haplotypes/genetics | 2 | 0.0 |
Immunoglobulins, Fc | 2 | 16.0 |
*Kidney Transplantation | 3 | 0.0 |
Vascular Cell Adhesion Molecule-1 | 5 | 6.0 |
Antigens, Differentiation, T-Lymphocyte/*physiology | 29 | 19.0 |
Molecular Probes/genetics | 2 | 2.0 |
*Liver Transplantation | 2 | 1.0 |
Bone Marrow Transplantation/immunology | 3 | 8.0 |
Endothelium, Vascular/cytology/*immunology | 2 | 6.0 |
Egtazic Acid/pharmacology | 2 | 1.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Polyenes/*pharmacology | 2 | 12.0 |
*Signal Transduction/drug effects | 3 | 3.0 |
Oligodeoxyribonucleotides/chemistry | 3 | 1.0 |
Antigens, CD28/*biosynthesis/*chemistry | 2 | 100.0 |
*Conserved Sequence | 2 | 1.0 |
Nucleic Acid Hybridization | 4 | 0.0 |
Transforming Growth Factor beta/*immunology | 2 | 25.0 |
Neoplasms/*immunology | 3 | 2.0 |
Calcium/*physiology | 3 | 2.0 |
Mice, Mutant Strains | 2 | 0.0 |
Antigens, CD19 | 3 | 1.0 |
Antigens, CD56 | 2 | 2.0 |
Cell Proliferation | 3 | 1.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Phosphotyrosine | 6 | 2.0 |
Tyrosine/*analogs & derivatives/metabolism | 2 | 3.0 |
Antigens, CD2 | 35 | 7.0 |
Cell Communication/*immunology | 2 | 4.0 |
Protein-Tyrosine Kinase/antagonists & inhibitors/*physiology | 2 | 20.0 |
Thymus Gland/*cytology | 2 | 3.0 |
T-Lymphocytes, Cytotoxic/drug effects/*immunology | 2 | 9.0 |
Antigens, Differentiation, B-Lymphocyte/*metabolism | 2 | 5.0 |
B-Lymphocytes/*physiology | 2 | 1.0 |
Interleukin-12 | 2 | 11.0 |
Antigens, Neoplasm/analysis | 2 | 0.0 |
Antigens, Surface/analysis | 4 | 0.0 |
Gene Rearrangement | 3 | 0.0 |
Genes, Immunoglobulin | 2 | 1.0 |
Interleukins/physiology | 2 | 13.0 |
Diglycerides/pharmacology | 2 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/physiology | 3 | 25.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Hodgkin Disease/immunology/*therapy | 2 | 66.0 |
Interleukin-2/*biosynthesis/secretion | 2 | 66.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Tyrosine/analogs & derivatives/metabolism | 2 | 1.0 |
Rabbits/immunology | 2 | 2.0 |
Antibodies/blood | 2 | 3.0 |
Intercellular Adhesion Molecule-1 | 12 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/physiology | 14 | 17.0 |
Antigens, CD18 | 3 | 3.0 |
T-Lymphocytes, Cytotoxic/physiology | 2 | 11.0 |
Interleukin-3/pharmacology | 2 | 0.0 |
Macaca nemestrina | 2 | 6.0 |
Cholera Toxin/pharmacology | 4 | 5.0 |
*Gene Expression Regulation/drug effects | 3 | 1.0 |
T-Lymphocytes/physiology | 2 | 1.0 |
Immune Sera/immunology | 2 | 1.0 |
HLA-D Antigens/immunology | 2 | 5.0 |
Receptors, Cell Surface/immunology | 5 | 14.0 |
Receptors, Cell Surface/*metabolism | 3 | 0.0 |
Histocompatibility Antigens Class I/*immunology | 3 | 2.0 |
Antigens, Surface/*physiology | 8 | 12.0 |
Antigens, Differentiation, T-Lymphocyte/biosynthesis/genetics/*physiology | 2 | 50.0 |
Antigens, Differentiation, T-Lymphocyte | 5 | 1.0 |
Receptors, Immunologic | 3 | 8.0 |
*Antigens, Differentiation, T-Lymphocyte | 3 | 9.0 |
T-Lymphocytes/*drug effects/immunology/metabolism | 2 | 14.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Monocytes/physiology | 4 | 3.0 |
Antigens, CD11 | 2 | 2.0 |
Staphylococcus aureus/*immunology | 4 | 4.0 |
Antigens, Differentiation/genetics/*physiology | 2 | 12.0 |
Immunoconjugates/pharmacology | 2 | 66.0 |
Lymphocytes, Tumor-Infiltrating/*physiology | 2 | 25.0 |
Immunoglobulins, Fab/immunology | 2 | 1.0 |
Oligonucleotide Probes | 2 | 0.0 |
Antigens, Surface/immunology | 4 | 2.0 |
Receptors, Nerve Growth Factor/biosynthesis/genetics/*physiology | 2 | 100.0 |
Receptors, Tumor Necrosis Factor/biosynthesis/genetics/*physiology | 2 | 33.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/immunology | 2 | 13.0 |
Restriction Mapping | 3 | 0.0 |
Genes, nef | 3 | 11.0 |
Histocompatibility Antigens/physiology | 2 | 25.0 |
Histocompatibility Antigens/analysis | 3 | 4.0 |
Histocompatibility Antigens/*physiology | 2 | 16.0 |
Receptors, Leukocyte-Adhesion/immunology | 2 | 16.0 |
Antigens, CD1 | 2 | 2.0 |
Thymus Gland/cytology/growth & development | 2 | 100.0 |
NF-kappa B/biosynthesis | 2 | 13.0 |
B-Lymphocytes/*immunology/physiology | 2 | 18.0 |
Genes, Structural | 3 | 0.0 |
Oligonucleotides/chemistry | 2 | 1.0 |
Polymorphism, Single Nucleotide/genetics | 2 | 0.0 |
Cyclosporins/*pharmacology | 4 | 11.0 |
Receptors, Antigen, T-Cell/*analysis | 3 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*analysis/physiology | 2 | 28.0 |
Piperazines/pharmacology | 2 | 1.0 |
Tacrolimus | 2 | 50.0 |
Cyclosporins/pharmacology | 4 | 10.0 |
Hybridomas/immunology | 2 | 1.0 |
Macrophages/drug effects/*immunology | 2 | 10.0 |
Antigens, Differentiation, T-Lymphocyte/analysis/*immunology | 3 | 13.0 |
CD4-Positive T-Lymphocytes/classification/*immunology | 2 | 33.0 |
Interleukins/pharmacology | 2 | 2.0 |
Cells, Cultured/drug effects | 2 | 2.0 |
Immunologic Techniques | 2 | 0.0 |
Antibodies, Monoclonal/physiology | 6 | 8.0 |
Interleukin-4 | 2 | 2.0 |
Interleukin-6 | 2 | 4.0 |
Peptide Library | 2 | 1.0 |
Ionophores/*pharmacology | 2 | 10.0 |
T-Lymphocytes/classification/immunology/*metabolism | 2 | 33.0 |
T-Lymphocytes/*immunology/metabolism/physiology | 2 | 28.0 |
Tetradecanoylphorbol Acetate | 3 | 4.0 |
DNA Replication | 2 | 0.0 |
Thymus Gland/metabolism | 2 | 2.0 |
Oncogene Proteins/metabolism | 2 | 2.0 |
Aging/*physiology | 2 | 0.0 |
Glycolysis | 2 | 3.0 |
*Endocytosis | 2 | 1.0 |
Promoter Regions (Genetics)/drug effects/immunology | 2 | 20.0 |
Transcription, Genetic/drug effects/immunology | 2 | 12.0 |
Membrane Proteins/genetics/immunology | 2 | 28.0 |
Virus Replication/genetics/immunology | 2 | 66.0 |
Proteins/*physiology | 2 | 1.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
CD4-Positive T-Lymphocytes/*immunology/secretion | 2 | 20.0 |
Protein-Serine-Threonine Kinases/physiology | 2 | 2.0 |
